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Ovarian cancer is one of the deadliest gynaecological cancers. A key contributing factor to its 
high mortality rate is its non-specific symptoms and lack of early detection, which results in 
most patients being diagnosed with advanced stage cancer. Ovarian cancer is highly 
metastatic, with a unique route of dissemination that is facilitated by the movement of cancer 
cells through ascitic fluid, which accumulates in the peritoneal cavities of patients with 
advanced ovarian cancer. Cancer cells can then adhere to the peritoneum, or the surfaces of 
other organs, and form tumour nodules. This mode of metastasis is poorly understood, and 
therefore warrants further investigation.  
Acquired resistance to currently available anticancer compounds is a common feature of 
advanced ovarian cancer, making the need for the development of alternative treatment 
options urgent. Resveratrol is a naturally-occurring food compound that has been shown to 
have some anti-cancer properties, including inhibition of angiogenesis, proliferation, and 
invasion, as well as induction of apoptosis. This study investigated the effects of resveratrol 
on several cellular processes known to contribute to cancer growth and survival using ovarian 
cancer tumour implants grown on chicken chorioallantoic membranes (CAMs) to mimic the 
growth of tumour nodules on the surface of the peritoneum during the early stages of 
metastasis. 
This study demonstrated that using the CAM model as a proxy for the peritoneum is an 
appropriate model for investigation into the early stages of metastasis in the context of 
advanced ovarian cancer. Results also showed that treatment with 91 µg resveratrol inhibited 
invasion of OVCAR-8 and SKOV-3 cells into the CAM. This dose of resveratrol also led to a 
reduction in the number of red blood cells in SKOV-3 tumour implants, whereas 46 µg was 
sufficient to have a similar effect in OVCAR-8 tumour implants. Resveratrol may therefore 
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Cancer is one of the leading causes of mortality worldwide, especially in developed countries 
such as the United States where it is the second leading cause of death after heart disease, as 
well as Australia and New Zealand, where it is the leading cause of death (Bray et al., 2018; 
Disney, 2016; Rebecca L. Siegel, Miller, & Jemal, 2018).  In 2018, there were an estimated 
18 million new cancer cases and more than 9.5 million deaths caused by cancer worldwide 
(Bray et al., 2018). Cancer therefore represents a major public health problem on a global 
scale.  
While many different types and subtypes of cancer exist, almost all cancer cells share several 
common characteristics, which are generally considered the ‘hallmarks’ of cancer (Hanahan 
& Weinberg, 2000). An important underlying characteristic shared by all cancers is genomic 
instability or increased mutability, as this is what allows mutations to accumulate, thus 
supporting the growth and progression of tumours (Hanahan & Weinberg, 2000; Hanahan & 
Weinberg, 2011). 
Of these common characteristics, several involve separating the growth of cancer cells from 
environmental signals (Hanahan & Weinberg, 2000). Whereas normal cells require the 
presence of growth signals in order to proliferate, cancer cells do not, possibly because they 
are able to produce their own proliferative signals (Evan & Vousden, 2001; Hanahan & 
Weinberg, 2000). Cancer cells are also typically insensitive to anti-proliferative signalling 
and will continue to proliferate, even in the presence of anti-growth signals or growth 
inhibition (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011). Normal cells can only 
progress through the cell cycle a given number of times before dying or becoming senescent, 
but cancer cells often have infinite replicative potential (Hanahan & Weinberg, 2000; 
Hanahan & Weinberg, 2011). In addition, cancer cells can develop mechanisms of evading 
programmed cell death (Bold, Termuhlen, & McConkey, 1997; Hanahan & Weinberg, 2000). 
Other hallmarks of cancer include sustained angiogenesis to provide tumours with all the 
nutrients they require to continue growing, and tissue invasion and metastasis, an often-
deadly characteristic of many late-stage malignancies (Fouad & Aanei, 2017; Hanahan & 
Weinberg, 2000; Yang & Weinberg, 2008; Ziyad & Iruela-Arispe, 2011).  
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1.2 Ovarian cancer 
Ovarian cancer is a major cause of mortality among women with gynaecological cancers (R. 
L. Siegel, Miller, & Jemal, 2016). Cancer death rates in general are slowly beginning to 
decline; however, statistics describing ovarian cancer have remained reasonably stable over 
the past two decades (Greenlee, Murray, Bolden, & Wingo, 2000; Jemal et al., 2006; Rebecca 
L. Siegel et al., 2018; Rebecca L. Siegel, Naishadham, & Jemal, 2012). In 2018, there were 
an estimated 295,000 new cases of ovarian cancer, and 140,000 deaths caused by ovarian 
cancer worldwide (Bray et al., 2018). The relative five-year survival of epithelial ovarian 
cancer is less than 50% (Torre et al., 2018). 
During its early stages, ovarian cancer is typically mostly asymptomatic, which makes early 
detection of the disease very difficult (Cannistra, 2004; R. L. Siegel et al., 2016). 
Consequently, patients are often only diagnosed with ovarian cancer after the disease has 
reached an advanced stage, and by this point chances of survival are typically quite low 
(Hassan, Chitcholtan, Sykes, & Garrill, 2016, 2018). Furthermore, late-stage disease is often 
difficult to treat effectively, particularly because commonly used chemotherapeutics are 
generally of limited efficacy with respect to ovarian cancer, as patients with recurring disease 
are likely to develop resistance to conventional chemotherapeutics (Cannistra, 2004; Huang 
et al., 2012; Kipps, Tan, & Kaye, 2013). Patients with advanced ovarian cancer also often 
suffer a poor quality of life due to a combination of the symptoms of the cancer itself, such as 
an accumulation of ascitic fluid in the peritoneal cavity, which is common among such 
patients and often causes considerable discomfort, and the harsh side effects of the treatment 
strategies employed to combat ovarian cancer (Cannistra, 2004).  
In general, ovarian tumours arise in the lining of the ovary, and spreading throughout the 
abdominal cavity and other internal organs is relatively straightforward from this site (Fagotti 
et al., 2010). The peritoneal membrane covers the visceral organs, along with the abdominal 
and pelvic cavities, and consists of an interstitial or stromal space between a layer of 
endothelial cells on one side and a layer of mesothelial cells on the other (Kipps et al., 2013). 
As tumours develop, malignant cells can shed and then float in the peritoneal fluid, which 
allows cancer cells to spread and develop into tumours in locations other than the ovary 
(Fagotti et al., 2010; Weidle, Birzele, Kollmorgen, & Rueger, 2016). Free-floating tumour 
cells in the peritoneal fluid can also interact with the mesothelial layer of the peritoneal 
14 
 
membrane, adhere to this layer of cells, and eventually grow on the surface of the peritoneal 
membrane as tumour nodules (Weidle et al., 2016).  
 
Figure 1.1 Proposed model of early metastasis of ovarian cancer. Malignant cells on the 
surface of the ovary undergo EMT, and then shed from the ovary into the peritoneal cavity. 
Cells then form aggregates, which secrete growth factors and cytokines to encourage the 
accumulation of ascitic fluid in the peritoneal cavity, which allows cellular aggregates to 
survive until they reach a secondary attachment site. Image reproduced with permission 




The clinical progression of ovarian cancer is divided into four main stages: at stage I, the 
disease is restricted to the ovaries alone; at stage II, cancer cells have migrated into pelvic 
organs and tissues; at stage III, the cancer has spread to the abdominal cavity or invaded the 
lymph nodes, or both; and at stage IV, distant metastases have been established (Jayson, 
Kohn, Kitchener, & Ledermann, 2014). As ovarian cancer progresses through these stages, 
survival rates decrease dramatically; for patients diagnosed with stage I disease, the five-year 
survival rate is approximately 80%, but this drops to 30% and 20% for stage III and IV 
disease respectively (Torre et al., 2018).  
Approximately 90% of ovarian cancers are epithelial in origin, and tumour cell morphology 
and molecular pathology can be used to further classify these as serous (high- or low-grade), 
endometrioid (high- or low-grade), clear cell, or mucinous (Cho & Shih, 2009; Jayson et al., 
2014). Whether the cancer is high- or low-grade depends primarily on the amount of solid 
tumour growth, and typically reflects the aggressiveness of the cancer (Cho & Shih, 2009). 
Serous carcinoma is the most common type of epithelial ovarian cancer (Cho & Shih, 2009). 
Mutations in the tumour suppressor gene TP53 are very common in high-grade serous 
ovarian cancer, whereas mutations in KRAS or BRAF are common in low-grade serous cancer 
(Cho & Shih, 2009; Jayson et al., 2014). Clinically, high-grade serous ovarian cancer is 
typically aggressive and affects mostly older women, whereas low-grade cancer is slower to 
develop and affects mainly younger women (Ayhan et al., 2009). Most ovarian cancer deaths 
occur in patients with advanced, high-grade serous ovarian cancer as this is the most common 
subtype (The Cancer Genome Atlas Research et al., 2011). The endometrioid and clear cell 
subtypes are the next most common, although they are both quite rare compared to the serous 
subtype, and the mucinous subtype is the least common (Cho & Shih, 2009). 
Treatment of advanced ovarian cancer typically involves surgery to remove as much of the 
cancer as possible; ‘optimal’ surgery refers to the removal of all tumours except nodules that 
are less than 1 cm in diameter, which can be very difficult to surgically remove (Pomel et al., 
2007). However, individual cancer cells can penetrate the layer of mesothelial cells on the 
peritoneal membrane, invade the interstitial space, and can then spread to other internal 
organs in the abdominal cavity (Weidle et al., 2016). Therefore, an in vivo model that mimics 
the development of small tumour nodules on the surface of the peritoneal membrane and their 
subsequent invasion further into the stromal area of this membrane may provide information 
needed for the development of more effective treatments for ovarian cancer.  
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1.3 The chicken chorioallantoic membrane (CAM) model 
The ability of ovarian tumour cells to detach from the ovary, adhere to, and invade the 
peritoneal membrane is often the basis of metastasis in ovarian cancer (Lokman, Elder, 
Ricciardelli, & Oehler, 2012). As such, research involving advanced ovarian cancer requires 
an in vivo model that can imitate this process. One method that can be used to replicate the 
natural environment of ovarian tumours and the spread of cancerous cells to the peritoneum is 
to use an animal cell model. The chicken chorioallantoic membrane (CAM) model is an 
example of such a system.  
 
Figure 1.2 Overview of the CAM model. Cancer cells are implanted on the surface of the 
upper CAM, and can then invade the epithelial layer and basement membrane. Cancer cells 
can then move into the vascular network and metastasise to distal portions of the CAM or 




The CAM is a very thin, highly vascularised membrane that surrounds developing chicken 
embryos (Durupt, Koppers-Lalic, et al., 2012). The membrane consists of an endoderm, 
mesoderm or stromal region, and an ectoderm, which is very similar to the peritoneal 
membrane (Lokman et al., 2012). Developing chicken embryos have immature immune 
systems and so can host tumour cells from various origins, including cancer cell lines derived 
from human patients, which are used in the present research (Durupt, Koppes-Lalic, et al., 
2012). The highly vascularised nature of the membrane also helps to enhance the efficiency 
of tumour cell grafting (Lokman et al., 2012). 
The CAM model has been widely used to study tumour invasion in vivo in different cancer 
types, including ovarian cancer (Lokman et al., 2012). Studies have shown that tumour cells 
grafted onto the CAM can develop into sizeable tumours and escape from the primary site by 
invading the mesodermal layer of the CAM, and eventually reach distal portions of the CAM 
(Deryugina & Quigley, 2008; Lokman et al., 2012). In this way, the CAM model can be used 
to replicate the process of metastasis in ovarian cancer (Deryugina & Quigley, 2008). 
Use of the CAM model, compared with the use of mammalian models, is also appealing as 
the requirements of this model are much more basic (Taizi, Deutsch, Leitner, Ohana, & 
Goldstein, 2006). The CAM model is cost-effective and simple, whereas mammalian models 
are often expensive, complex, and entail large space requirements and time-consuming 
studies, all of which can make them impractical (Durupt, Koppes-Lalic, et al., 2012; Taizi et 
al., 2006). Furthermore, using the CAM model as opposed to mammalian models minimises 
the amount of testing carried out on sentient animals (Taizi et al., 2006). The key limitations 
of the CAM model are that it already contains a well-developed vascular network, which can 
make it difficult to determine the true extent of angiogenesis, and that non-specific 
inflammatory reactions may occur as a consequence of the implantation of tumour cells (D. 
Ribatti, 2010). In this case, these drawbacks are outweighed by the significant advantages of 






Early during the formation of an embryo, a primary vascular plexus is formed via a process 
called vasculogenesis (Risau, 1997). After this original network has been formed, 
angiogenesis, or the formation of new blood vessels from existing ones, can occur to expand 
this network and increase its complexity (Karamysheva, 2008). 
Under normal circumstances, angiogenesis is tightly regulated, and will only occur under 
specific conditions (Karamysheva, 2008). It is an important process, but dysfunctional 
angiogenesis can have serious repercussions (Karamysheva, 2008; Nishida, Yano, Nishida, 
Kamura, & Kojiro, 2006). Excessive formation of new blood vessels and insufficient 
development of blood vessels can both contribute to severe human conditions including 
ischemic and inflammatory diseases, as well as cancer (Karamysheva, 2008; Potente, 
Gerhardt, & Carmeliet, 2011). Angiogenesis is necessary for the development of tumours; 
without adequate blood supply, tumour nodules cannot grow beyond approximately 100 to 
200 µm2, as hypoxia will lead to the death of the tumour cells that are too distant from any 
blood vessels (Folkman, 2006; Nishida et al., 2006; Schmitt & Matei, 2012; Ziyad & Iruela-
Arispe, 2011). 
The general pathways of angiogenesis are largely the same whether it is occurring during 
normal vascular growth or in tumours (Ziyad & Iruela-Arispe, 2011). However, tumour 
angiogenesis lacks feedback regulatory control. Where normal blood vessels are evenly 
distributed and highly ordered, tumour vasculature tends to be unevenly distributed, with 
irregular branching patterns and chaotic networks (Ziyad & Iruela-Arispe, 2011). Tumour 
vasculature is generally unstructured, fragile, and hyper-permeable (Ziyad & Iruela-Arispe, 
2011). This can reduce the efficacy of chemotherapeutics, as the efficiency of distribution of 
chemotherapeutic agents around tumours is likely to be impaired (Schmitt & Matei, 2012; 
Ziyad & Iruela-Arispe, 2011). 
There are essentially two main mechanisms of angiogenesis: sprouting and non-sprouting 




Figure 1.3 Angiogenesis may occur via sprouting or intussusception. Image reproduced 





1.4.1 Sprouting angiogenesis 
 
As its name suggests, sprouting angiogenesis is characterised by endothelial cells sprouting 
out from an existing blood vessel and growing towards an angiogenic signal (Adair & 
Montani, 2010). Angiogenic stimuli, such as hypoxia or inflammation, can trigger the release 
of angiogenic signalling molecules, including vascular growth factors and angiogenic 
chemokines (Carmeliet & Jain, 2011; Karamysheva, 2008). These molecules then bind to 
their cognate receptors, which are typically expressed on the surface of endothelial cells 
(Semenza, 2007). This leads to activation of signal transduction pathways that stimulate 
angiogenesis.  
In response to angiogenic signalling, matrix metalloproteinases (MMPs), along with other 
proteinases, locally degrade the basement membrane and extracellular matrix (ECM) close to 
the angiogenic stimulus (Carmeliet, 2000; Domenico Ribatti & Crivellato, 2012). This leads 
to the destabilisation of the existing, mature blood vessels, which is compounded by the 
weakening of interactions between endothelial cells (Carmeliet, 2000; Domenico Ribatti & 
Crivellato, 2012). The consequent increased permeability of the existing vasculature allows 
for the migration of plasma proteins through the endothelial cell layer, where they form a 
provisional ECM scaffold (Carmeliet & Jain, 2011). 
Endothelial cells can then migrate to this newly formed ECM, where they begin to assemble 
into a solid cord (Carmeliet, 2000; Carmeliet & Jain, 2011; Domenico Ribatti & Crivellato, 
2012). A subset of endothelial cells become ‘tip cells’, which are highly migratory and 
respond to angiogenic signals, but undergo minimal proliferation (Domenico Ribatti & 
Crivellato, 2012; Rice, Gerwins, & Kilarski, 2012). Other endothelial cells proliferate 
actively to form the ‘stalk’ (Carmeliet & Jain, 2011). These stalk cells also form a vascular 
lumen, synthesise a new basement membrane, and associate with pericytes (Carmeliet & Jain, 
2011; Domenico Ribatti & Crivellato, 2012). Finally, stalk cells stop proliferating and 
functional contacts between these endothelial cells are re-established in the newly formed 
blood vessel (Domenico Ribatti & Crivellato, 2012). 
Key proteins involved in this type of angiogenesis include vascular growth factors such as the 
vascular endothelial growth factor (VEGF) family of proteins, transforming growth factors 
(TGF), fibroblast growth factors (FGF), and angiopoietin, along with all of their associated 
receptor proteins (Karamysheva, 2008). Cytokines, including tumour necrosis factor (TNF)-α 
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1.4.2 Intussusceptive angiogenesis 
 
Non-sprouting angiogenesis, also called intussusceptive angiogenesis or intussusceptive 
microvascular growth, is the process of forming new blood vessels by splitting pre-existing 
vessels into two functional vessels using trans-capillary pillars (Rice et al., 2012; Risau, 
1997). This method of blood vessel formation is significantly faster and less metabolically 
demanding than sprouting angiogenesis (Domenico Ribatti & Djonov, 2012; Rice et al., 
2012). Furthermore, normal levels of vascular permeability are maintained, and the 
proliferation of endothelial cells is not an immediate requirement, as this type of angiogenesis 
simply involves the migration and remodelling of existing vasculature (Hillen & Griffioen, 
2007; Rice et al., 2012). It is therefore an efficient means of expanding existing capillary 
networks, but in contrast to sprouting angiogenesis, intussusceptive angiogenesis is not an 
invasive process, and cannot be used to vascularise regions that were originally avascular 
(Burri, Hlushchuk, & Djonov, 2004; Paku et al., 2011). The exact molecular mechanism is 
incompletely understood, although it has been suggested that VEGF, angiopoietin, platelet-
derived growth factor (PDGF), and erythropoietin may play a role (Domenico Ribatti & 
Djonov, 2012). 
While the mechanistic details are still under investigation, the morphological changes 
involved in non-sprouting angiogenesis are well-described in the literature (Rice et al., 2012).  
Endothelial cells opposite one another, from the same blood vessel, are initially drawn 
together to form a ‘transluminal bridge’ (Burri et al., 2004). A small perforation, about 1 µm 
across, is then formed in the endothelial bilayer, resulting in a hollow, cylindrical bridge 
through the lumen (Burri et al., 2004; Rice et al., 2012). Pericytes migrate to this perforation, 
stabilising the junctions between endothelial cells and forming a new basement membrane 
(Rice et al., 2012). Extracellular matrix components such as collagen accumulate within the 
pillar, and the surrounding endothelial cells reorient themselves to continue elongating the 
pillar and splitting the vessel (Rice et al., 2012). 
Intussusceptive angiogenesis can be induced by increased blood flow and shear stress, both of 
which are typical of tumour vasculature (Domenico Ribatti & Djonov, 2012). In addition, 
some research suggests that intussusceptive angiogenesis might be less dependent on VEGF 
signalling than sprouting angiogenesis, meaning that angiogenesis inhibitors designed to 
target this signalling pathway may have a limited effect on intussusceptive angiogenesis 
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(Rice et al., 2012). Switching from sprouting to intussusceptive angiogenesis may therefore 
represent an adaptive response to treatment with various anti-angiogenic compounds; that is, 
inhibition of sprouting angiogenesis may induce intussusceptive angiogenesis (Hillen & 






Cancer cells at the primary tumour site can invade through the basement membrane of blood 
vessels and enter the circulation, allowing tumour cells to reach distant metastatic sites 
(Yeung et al., 2015). In addition, in patients with advanced ovarian cancer, passive 
dissemination of tumour cells is also possible. Cancer cells that become detached from the 
primary tumour may be carried throughout the peritoneal cavity by ascitic fluid to a 
metastatic site, where they adhere to the surface of an organ, tissue, or the peritoneum itself 
(Yeung et al., 2015). Once attached to the surface of the peritoneal membrane, tumour cells 
can proliferate and invade the mesothelium (Yeung et al., 2015). Ascitic fluid components 
can support this invasion of tumour cells by inducing secretion of matrix-degrading 
proteinases like MMPs (Yeung et al., 2015). 
The process of invasion requires the conversion of stationary epithelial cells, which are 
connected securely to one another via specialised adhesion complexes, to mesenchymal cells, 
which do not have any such junctions and are motile (Nakayama, Nakayama, Katagiri, & 
Miyazaki, 2012; Yang & Weinberg, 2008). This mechanism for detachment of tumour cells 
from the epithelial cell layer and the gain of motility, known as epithelial-mesenchymal 
transition (EMT), enables tumour cell invasion and metastasis (Krakhmal, Zavyalova, 
Denisov, Vtorushin, & Perelmuter, 2015). 
 
Figure 1.4 EMT involves the transition of epithelial cells into mobile mesenchymal cells. 
Common markers of both epithelial and mesenchymal cells are listed. Image reproduced with 




There are several crucial events that occur during EMT. One is a change in the cell’s polarity; 
epithelial cells have apical-basal polarity as they are associated with a basement membrane, 
whereas mesenchymal cells have front-rear polarity and are not anchored to any substrate 
(Yang & Weinberg, 2008). Alongside this change in polarity is the dissolution of epithelial 
cell-cell junctions, allowing detachment of cells from the epithelial cell layer (Kalluri & 
Weinberg, 2009; Krakhmal et al., 2015; Lamouille, Xu, & Derynck, 2014). This involves the 
loss of cell-adhesion molecules such as E-cadherin, which may be mediated by various 
transcriptional repressors, such as Slug, Snail, or Twist (van Zijl, Krupitza, & Mikulits, 
2011). 
These changes are followed by reorganisation of the cytoskeleton and changes in cell shape, 
enabling cell elongation and motility (Lamouille et al., 2014). Mesenchymal cells are capable 
of projecting protrusions or lamellipodia and have increased contractility (Lamouille et al., 
2014). Changes in gene expression then often occur to increase migratory and invasive 
properties, including downregulation of epithelial gene expression, increased expression of 
genes that define the mesenchymal phenotype, and increased formation of protrusions and 
motility (Krakhmal et al., 2015; Lamouille et al., 2014). The net result of these changes is the 
transition of an epithelial cell into a mesenchymal one, which has the ability to migrate and 




Figure 1.5 Cell phenotypes that are associated with invasion through the ECM. Image 
reproduced with permission (Provenzano, Eliceiri, & Keely, 2009). 
 
Once tumour cells are capable of invasion, they may do this as individual cells or as a 
collection of cells simultaneously, and in each case invasion may occur via either a 
mesenchymal or amoeboid mechanism (Krakhmal et al., 2015). The mesenchymal, or 
fibroblast-like, mechanism of invasion is reasonably slow and inefficient, with cells only 
moving at a rate of about 0.1 – 1.0 µm per minute (van Zijl et al., 2011). This mechanism 
involves the formation of a protrusion from one of the poles of a cell, and then the formation 
of focal adhesions between the cell and ECM, which is dependent upon the activity of 
integrins (Krakhmal et al., 2015). Integrins then mediate the assembly of focal contacts, and 
proteolytic enzymes, including MMPs, locally degrade and remodel the ECM and basement 
membrane (Krakhmal et al., 2015; van Zijl et al., 2011). Contractions of the cell body, 
facilitated by myosin-mediated changes in the polarisation of the actin cytoskeleton, enable 
movement of the cell and the trailing edge is ‘pulled’ along through the region of degraded 
ECM (Krakhmal et al., 2015). 
In contrast to the mesenchymal invasion mechanism, amoeboid invasion is much more rapid, 
with cells moving at speeds of up to 20 µm per minute (van Zijl et al., 2011). This type of 
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invasion is characterised by weak interactions between cells and the ECM (Krakhmal et al., 
2015). Amoeboid invasion is not reliant on integrins, and does not require degradation of the 
ECM, so no proteolytic enzymes are involved in this mechanism of invasion (Krakhmal et 
al., 2015). Movement via this type of invasion is achieved through successive high-speed 
cycles of cell body expansion and contraction, mediated by the actomyosin cortex (Krakhmal 
et al., 2015; Panková, Rösel, Novotný, & Brábek, 2010). Activation of the Rho/ROCK 
signalling pathway, which is mainly involved in regulating the shape and movement of cells, 
enhances the contractility of these cells, allowing them to modify their shape so that they may 





1.6 Cell proliferation 
 
 
Figure 1.6 The cell cycle. Image reproduced with permission (Hartwell & Kastan, 1994). 
 
The cell cycle consists of a cell growth phase (G1 phase), followed by the synthesis of DNA 
(S phase), followed by more growth (G2 phase), and finally mitosis and cytokinesis (M 
phase), ultimately producing two identical daughter cells. Cells which divide rapidly 
continually go through this cell cycle, producing more and more daughter cells (Cooper, 
2000). In contrast, cells which divide more slowly, or not at all, may exit the cell cycle at G1 
phase, before reaching S phase, and enter what is known as G0 phase, a resting state where 
cells are not actively preparing to divide (Cooper, 2000).  
Progression through the cell cycle is mediated by cell cycle regulators, including cyclins, 
cyclin dependent kinase (Cdk) proteins, and Cdk inhibitor (CKI) proteins (Lim & Kaldis, 
2013). These regulatory molecules respond to both intra- and extracellular cues; for example, 
the presence of growth factors will stimulate progression through the cell cycle, whereas 
DNA damage will halt the cell cycle (Lim & Kaldis, 2013). Cdk proteins are activated by the 
binding of relevant cyclins, and can then phosphorylate target proteins to either activate or 
inactivate them (Lim & Kaldis, 2013). Cyclins are regulatory proteins that control Cdk 
activity and substrate specificity (Lim & Kaldis, 2013). The activity of Cdk/cyclin complexes 
is carefully controlled by CKI proteins, which can halt progression through the cell cycle, 
when needed, by inhibiting Cdk activity (Lim & Kaldis, 2013). 
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There are several checkpoints in the cell cycle, of which two of the most important are the G1 
and G2 checkpoints. At the G1/S transition, the cell is checked for appropriate size, nutrients, 
growth factors, and for any DNA damage, before DNA replication can proceed (Cooper, 
2000). At the G2/M transition, the cell is, again, checked for DNA damage, along with a 
check of the completeness of DNA replication, before cell division occurs (Cooper, 2000). 
Abnormal regulation of the cell cycle, caused primarily by the accumulation of mutations, 
can lead to cancer. Tumour cells can proliferate well beyond the constraints that normally 
limit growth in healthy cells (Evan & Vousden, 2001). In some cases, cancer cells no longer 
require mitogenic signals in order to proliferate – that is, they will continue to proliferate 
even in the absence of proliferative signals (Evan & Vousden, 2001). In other cases, cancer 
cells are able to bypass checkpoints in the cell cycle and divide even if they do not meet the 
usual criteria for progression through the cell cycle (Evan & Vousden, 2001). Loss of the 
tumour suppressor protein p53, which normally mediates the G2/S transition, allows cells to 
progress to S phase without undergoing the appropriate checks, and subsequently allows the 
formation of mutation-harbouring daughter cells (Alsina-Sanchís et al., 2017). 
In healthy tissues, the production and release of signals that promote progression through the 
cell cycle are carefully controlled; however, cancer cells often proliferate independently of 
these growth factors as they are able to overexpress positive proliferative signals, or elevate 
the levels of receptors on cell surfaces to make those cells hyper-sensitive to proliferative 
signalling, which would limit cell growth under normal circumstances (Evan & Vousden, 
2001; Hanahan & Weinberg, 2011). Disruption of negative feedback mechanisms and 
evasion of growth suppression mechanisms may also enable cells to continue to proliferate 
when, in a healthy system, proliferation would be inhibited (Hanahan & Weinberg, 2011). In 
addition, normal cells may only progress through the cell cycle a limited number of times 
before becoming senescent or dying, whereas cancer cells have essentially infinite replicative 




1.7 Cell death 
 
Cell death is a critical to maintaining healthy tissues; it is a mechanism for eliminating cells 
that are no longer needed, or are potentially dangerous to the rest of the organism. There are 
many different pathways through which cells may die, but two of the most common are 







Apoptosis is a programmed, controlled form of cell death. It is an essential cellular process, 
critical to various developmental processes, the healing of wounds, and the removal of 
deteriorating or otherwise damaged cells (Elmore, 2007). Apoptosis also plays a crucial role 
in the proper development and functioning of the immune system as it is the process by 
which cells invaded by pathogens are eliminated (Elmore, 2007). There are two key pathways 
through which apoptosis usually occurs: the extrinsic pathway, and the intrinsic pathway (R. 
S. Y. Wong, 2011).   
. 
Figure 1.7 Schematic representation of both the intrinsic and extrinsic apoptotic pathways. 
Image reproduced with permission (de Vries, Gietema, & de Jong, 2006). 
 
The extrinsic apoptotic pathway, or the ‘death receptor pathway’, is triggered by the binding 
of a ligand to its corresponding ‘death receptor’ (R. S. Y. Wong, 2011). One of the most 
commonly described examples of this is the binding of the Fas ligand (FasL) to its receptor 
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(Fas), and the subsequent binding of the adapter protein, Fas-associated death domain 
(FADD) (Bold et al., 1997; R. S. Y. Wong, 2011). Another common example is the binding 
of tumour necrosis factor (TNF) to its receptor (TNFR), and then the binding of TNFR-
associated death domain (TRADD) (Bold et al., 1997; Elmore, 2007; R. S. Y. Wong, 2011). 
This whole complex of the ligand, receptor, and associated adapter protein form a death 
inducing signalling complex (DISC) (R. S. Y. Wong, 2011). The DISC then facilitates the 
assembly and activation of pro-caspase-8, which subsequently activates pro-caspase-3 
(Elmore, 2007). 
The intrinsic pathway of apoptosis, sometimes referred to as the mitochondrial apoptotic 
pathway, is typically triggered by an internal stimulus, such as the loss of apoptotic 
suppression or the presence of radiation, toxins, hypoxia, or free radicals (Elmore, 2007). 
Any of these events can lead to the loss of the mitochondrial transmembrane potential, which 
disrupts the integrity of the outer mitochondrial membrane (R. S. Y. Wong, 2011). Increased 
permeability of the mitochondrial membrane facilitates the release of pro-apoptotic molecules 
such as cytochrome c, Smac/DIABLO, and HtrA2/Omi into the cytosol (Elmore, 2007). 
Cytochrome c, once it is present in the cytoplasm, activates pro-caspase 9, which then 
activates pro-caspase-3 (R. S. Y. Wong, 2011). When the pro-apoptotic mitochondrial 
protein, second mitochondria-derived activator of caspase/direct inhibitor of apoptosis 
binding protein with low pI (Smac/DIABLO), is present in the cytosol it can act as an 
antagonist of inhibitor of apoptosis proteins and thereby induce apoptosis (Martinez-Ruiz, 
Maldonado, Ceballos-Cancino, Grajeda, & Melendez-Zajgla, 2008). High-temperature 
requirement (HtrA) proteins are a family of serine proteases; HtrA2/Omi resides in the 
mitochondrial intermembrane space, and also facilitates apoptosis by binding and 
antagonising inhibitor of apoptosis proteins (Vande Walle, Lamkanfi, & Vandenabeele, 
2008). 
Both the extrinsic and intrinsic apoptotic pathways converge at a common step: the activation 
of pro-caspase-3 at the beginning of what is known as the ‘execution pathway’ (Elmore, 
2007; R. S. Y. Wong, 2011). Caspase-3 activates various endonucleases, including apoptosis 
inducing factor (AIF), endonuclease G, and caspase-activated DNase (CAD), which then 
mediate the degradation of chromosomal DNA (Elmore, 2007). Caspase-3 also activates 
proteases, leading to the degradation of nuclear and cytoskeletal proteins and the 
reorganisation of cytoskeletal components (Elmore, 2007; R. S. Y. Wong, 2011). The 
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cytoplasm and nuclear chromatin are then condensed and the nucleus is broken down (R. S. 
Y. Wong, 2011). This all manifests morphologically as shrinkage of the cell, condensation of 
chromatin, and blebbing of the plasma membrane (Kerr, Winterford, & Harmon, 1994). 
‘Apoptotic bodies’, composed of cytoplasm, organelles, and possibly nuclear fragments, all 
encased within a plasma membrane, are then formed (R. S. Y. Wong, 2011). These are then 
rapidly phagocytosed by macrophages, which are recruited to the site of the apoptotic cell by 
phosphatidylserine residues which usually line the inside of cell membranes, but which are 
exposed during apoptosis (Elmore, 2007). 
When it occurs normally, apoptosis is a very useful cellular event. However, inappropriate 
levels of apoptosis – too much or too little – can have severe consequences (Bold et al., 1997; 
Elmore, 2007). Dysfunctional apoptosis is implicated in various human conditions, including 
many types of cancer, neurological disorders, cardiovascular disorders, and autoimmune 
disease (Elmore, 2007; Favaloro, Allocati, Graziano, Di Ilio, & De Laurenzi, 2012). An error 
in an apoptotic pathway could cause the survival of malignant cells, which would otherwise 
be eliminated by the cell under normal circumstances (R. S. Y. Wong, 2011). There are 
multiple possible apoptotic pathways, each of which is complex, with many different proteins 
and other molecules playing a role in the process, meaning that there are numerous 
opportunities for defects to arise in these pathways. 
While there are many proteins involved in apoptosis, there are several key groups of proteins 
which play a critical role. One such group is the caspases, or cysteine-aspartic acid proteases 
(Bold et al., 1997; R. S. Y. Wong, 2011). These are enzymes that cleave proteins at specific 
amino acid residues during apoptosis (R. S. Y. Wong, 2011). Caspases 2, 8, 9, and 10 are 
known as ‘initiator caspases’, and they are closely coupled to pro-apoptotic signals (R. S. Y. 
Wong, 2011). For example, the binding of FasL to Fas leads to the activation of pro-caspase-
8, and the binding of TNF to TNFR leads to the activation of pro-caspase-10 (Elmore, 2007). 
Once activated, these initiator caspases will cleave, thereby activating, a group of 
downstream caspases known as ‘effector caspases’, including caspases 3, 6, and 7 (R. S. Y. 
Wong, 2011). 
Another key group of proteins is the Bcl-2 family of proteins. There are a large number of 
these proteins, and they are responsible for regulating the permeabilization of the 
mitochondrial membrane in the intrinsic apoptotic pathway (Elmore, 2007; R. S. Y. Wong, 
2011). Some Bcl-2 family proteins are pro-apoptotic proteins (such as Bax and Bak), and so 
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disrupt the integrity of the mitochondrial membrane, allowing the release of cytochrome c 
into the cytosol and initiating the apoptotic signalling cascade (Bold et al., 1997; Elmore, 
2007). However, some members of this family are pro-survival proteins (including Bcl-2 and 
Bcl-XL), which inhibit apoptosis (Bold et al., 1997; Elmore, 2007). 
As detailed above, many cancer types, including ovarian cancer, often involve dysfunctional 
apoptosis. Inappropriate expression or activity of pro- and anti-apoptotic proteins can derail 
normal apoptosis; for example, increased expression of anti-apoptotic proteins such as Bcl-2, 
and decreased expression of pro-apoptotic proteins such as Bax, can lead to the inhibition of 
apoptosis (Bold et al., 1997). In addition, changes in the expression or activity of proteins 
which have a crucial role in apoptosis, such as caspases and death receptors, may also reduce 
the efficiency of apoptosis (Bold et al., 1997). 
Ovarian cancer cells are often less sensitive to apoptotic stimuli than healthy cells (Bast Jr, 
Hennessy, & Mills, 2009; Bold et al., 1997; Glinsky, Glinsky, Ivanova, & Hueser, 1997). 
This is problematic, not only because reduced apoptosis allows malignant cells to survive, but 
also because disruptions to apoptosis are often linked with resistance to common modes of 
therapy (Bold et al., 1997; Elmore, 2007; R. S. Y. Wong, 2011). Some therapy strategies, 
including radiation therapy and some chemotherapeutic agents, work by triggering apoptosis 
(Bold et al., 1997). Where apoptosis is dysfunctional, these treatments may not be very 
effective, as cancer cells are able to resist programmed cell death (Bold et al., 1997; Kerr et 
al., 1994). 
Disruption of apoptosis is also important for facilitating metastasis, as detachment of 
epithelial cells from the ECM is likely to induce apoptosis, unless apoptosis is dysfunctional 
(Bold et al., 1997; Glinsky et al., 1997). Therefore, it is unsurprising that highly metastatic 









Figure 1.8 Structural changes occurring in cells as they undergo necrosis or apoptosis. 
Image reproduced with permission (Goodlett & Horn, 2001). 
 
In contrast to apoptosis, necrosis is an uncontrolled mode of cell death, which usually occurs 
as a consequence of disruption to the cell’s energy supply or direct damage to the cell 
membrane (Majno & Joris, 1995). Morphologically, necrosis is quite different from 
apoptosis. Necrosis typically involves the swelling of necrotic cells, the formation of 
cytoplasmic vacuoles and blebs, distension of the endoplasmic reticulum, and the swelling of 
cellular components such as the mitochondria and lysosomes (Elmore, 2007). This eventually 
leads to the disruption of the cell membrane and the release of the cell contents into the 
surrounding interstitial tissue, which often ultimately leads to the initiation of an 
inflammatory response (Bold et al., 1997).  
The presence of necrosis is often associated with poor prognosis across a variety of tumour 
types (Bredholt et al., 2015). Rapidly proliferating tumour cells will eventually outgrow their 
blood supply, leading to local hypoxia (Dutta et al., 2012). Hypoxia induces cell death by 
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way of both apoptosis and necrosis (Shimizu et al., 1996). Necrotic cells release pro-
inflammatory cytokines, which can stimulate angiogenesis by upregulating expression of 
angiogenic molecules, including VEGF, FGF, and MMPs (Bredholt et al., 2015). Thus, 
necrosis can support the progression of tumours, and it follows that necrosis is typically 
associated with aggressive tumour types, advanced stage disease, and decreased patient 




Resveratrol was first isolated in 1940 from the roots of white hellebore, but it was not until 
1992 that it began to gain attention, initially for its cardioprotective effects (Baur & Sinclair, 
2006). Its anticancer properties were not identified until 1997, when it was observed that 
resveratrol inhibited cellular events that are involved in all three stages of carcinogenesis: 
initiation, promotion, and progression (Jang et al., 1997). 
 
Figure 1.9 trans-Resveratrol. Image reproduced with permission (Kraft, Parisotto, 
Schempp, & Efferth, 2009). 
 
Resveratrol is a polyphenolic phytoalexin that occurs naturally in a range of plant species, 
including various grapes and berries, and is perhaps most widely known as a component of 
red wine (Bishayee, 2009; Hogg, Chitcholtan, Hassan, Sykes, & Garrill, 2015; Villa-Cuesta, 
Boylan, Tatar, & Gruppuso, 2011). It can exist as either in cis or trans conformations, but the 
trans conformation predominates in nature and this is the isomer which has been studied and 
found to have anti-tumour activity (Kraft et al., 2009). 
Many in vitro studies to investigate the anticancer effects of resveratrol have thus far yielded 
promising results, suggesting that resveratrol may be able to slow tumour progression (Hogg 
et al., 2015). It has antioxidant properties, which means that it may prevent tumour initiation; 
it has also been shown to prevent angiogenesis and induce apoptosis (Kraft et al., 2009). In 
addition, resveratrol is not toxic to healthy cells, and has multiple molecular targets in various 
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pathways, so chemoresistance-inducing mutations may be overcome (Kraft et al., 2009). 
These factors make resveratrol a promising chemotherapeutic candidate. 
However, the bioavailability of resveratrol is low, which could interfere with its successful 
application in vivo (Hogg et al., 2015; Kraft et al., 2009). The results of in vivo studies 
investigating the effects of resveratrol are somewhat inconsistent: in some experiments, a 
chemo-preventative effect is observed, while in others there is no observable benefit to 
treatment with resveratrol (Baur & Sinclair, 2006). It is therefore difficult to draw strong 




1.9 Cell line selection 
 
In the present study, the effects of resveratrol on ovarian cancer growth and progression are 
investigated using two cell lines: OVCAR-8, and SKOV-3. Due to the highly heterogenous 
nature of ovarian cancer, it is important that appropriate cell lines are selected. Diversity 
among these cancer cell lines is important, as it is necessary to investigate a range of subtypes 
and cell lines in order to evaluate the efficacy of the treatment overall. The OVCAR-8 cell 
line has been reported to possibly represent the most common subtype of ovarian cancer: 
high-grade serous (Domcke, Sinha, Levine, Sander, & Schultz, 2013). The SKOV-3 cell line 
is still widely used in ovarian cancer research; however, is no longer believed to be 
representative of the high-grade serous subtype (Domcke et al., 2013). Nonetheless, it still 
presents a useful study tool, as results from this cell line can be compared with results from 




1.10 Hypotheses and aims 
The progression of advanced ovarian cancer is a complex process that is poorly understood, 
and this limits our understanding of the biology of this disease. To advance our understanding 
of the biology underlying advanced ovarian cancer, a pre-clinical model system that attempts 
to replicate the natural environment of tumours in the body, while still being reasonably 
simple, is essential. 
In the context of advanced ovarian cancer, ideal anticancer compounds should be cost-
effective, readily available, and have minimal to no adverse side effects, while still being 
effective at slowing the development of advanced ovarian tumours. 
I hypothesise that resveratrol will inhibit the growth of ovarian tumours in the CAM model. 
1.10.1 Aims 
 
To study the effects of resveratrol on ovarian cancer growth and progression using the CAM 
model.  
To study the effect of resveratrol on the number of red blood cells present in tumour 
implants. 
To study the effect of resveratrol on secretion of VEGF. 
To study the effect of resveratrol on invasion of tumour cells. 
To study the effect of resveratrol on expression of Ki67.  








2.1.1 General solutions, buffers, and media 
 
2.1.1.1 1x Phosphate-buffered saline (PBS) 
 
1x PBS was prepared using 137 mM sodium chloride (NaCl), 10 mM disodium phosphate 
(Na2HPO4), 1.76 mM monopotassium phosphate (KH2PO4), 2.7 mM potassium chloride 
(KCl), hydrochloric acid (HCl) to adjust pH to 7.4 and Milli Q water to make a final volume 
of 1 L. 
2.1.1.2 10x Trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA) 
 
10x Trypsin-EDTA was prepared by dissolving 1 mM Trypsin powder and 25.7 mM EDTA 
in 1x PBS. pH was adjusted to 8 using sodium hydroxide. Final volume was 200 mL. 
2.1.1.3 Dulbecco’s modified Eagle medium (DMEM) 
 
DMEM base media prepared up using one packet of Alpha medium and 44 mM sodium 
bicarbonate (NaHCO3) in 1 L Milli Q water. pH was adjusted to between 7.1 and 7.3 using 
sodium hydroxide (NaOH). This media was then filtered in a cell culture laminar flow 
cabinet. 
This base media was supplemented with 100 mL D-FBS, PenStrep antibiotics at a 
concentration of 100 units/mL penicillin and 100 µg/mL (172 µM) streptomycin, 2 mM 
GlutaMAX, and 0.2 µM Fungizone. This solution is hereafter referred to as ‘working media’. 
 
2.1.1.4 Fixing solution 
 




2.1.2 H&E staining solutions and buffers 
 
2.1.2.1 Scott’s tap water 
 
Scott’s tap water was prepared by dissolving 41.7 mM sodium bicarbonate (NaHCO3) and 
166 mM magnesium sulphate (MgSO4) in 1 L Milli Q water. 
2.1.2.2 Differentiation buffer 
 
Differentiation buffer was prepared using 70 mL 100% ethanol and 30 mL Milli Q water. 
2.1.2.3 Eosin 
 
Eosin solution was prepared using 3.8 mM eosin Y stock, 80 mL Milli Q water, 320 mL 95% 
ethanol, and 0.4 mL acetic acid. 
 
2.1.3 Immunohistochemistry solutions and buffers 
 
2.1.3.1 Antigen retrieval buffer 
 
Antigen retrieval buffer was prepared by dissolving 20 mM Tris base in Milli Q water and 
adjusting pH to 9 using EDTA. Final volume was 2 L.  
2.1.3.2 Membrane permeabilization buffer 
 
Membrane permeabilization buffer was prepared using 100 mL 1x PBS and 0.1 mL Triton X-
100. 
2.1.3.3 Wash buffer 
 
Wash buffer was prepared using 1 L 1x PBS and 1 mL Tween 20. 




Mouse and Rabbit Specific HRP/AEC (ABC) Detection IHC Kit, purchased from ABCAM, 
contains: 
 AEC Single Solution 
 Biotinylated Goat Anti-Polyvalent 
 Hydrogen Peroxide Block 
 Protein Block 
 Streptavidin-Peroxidase 
2.1.3.5 Bovine serum albumin (BSA) 
 
4% BSA was prepared using 100 mL 1x PBS and 4 g BSA 
 
2.1.4 TUNEL assay solutions 
 
2.1.4.1 2 M Tris-HCl (pH 7.8) 
 
2 M Tris-HCl was prepared by dissolving 2 M Tris base in Milli Q water and adjusting pH to 
7.8 using concentrated HCl. Final volume was 100mL. 
2.1.4.2 1x Tris-buffered saline (TBS) 
 
1x TBS was prepared using 10 mL 2 M Tris-HCl (pH 7.8), 140 mM NaCl and 1 L Milli Q 
water. 
2.1.4.3 Kit (ab206386) 
 
TUNEL assay kit – HRP-DAB, purchased from ABCAM, contains: 
 25x Conjugate 
 Blocking Buffer 
 DAB Solution 1 (DAB concentrate) 
 DAB Solution 2 (substrate reaction buffer) 
 Methyl green counterstain 
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 Proteinase K 
 Stop Buffer 
 TdT Enzyme 
 TdT Equilibration Buffer 







2.2.1 Frozen tissue sections 
 
2.2.1.1 Preparation of frozen samples 
 
Tumour implants, grown from OVCAR-8 or SKOV-3 cancer cells, and surrounding CAM 
were provided by my co-supervisor, Dr Chitcholtan. These were prepared using cancer cells 
(OVCAR-8, SKOV-3) encapsulated in collagen gels and fertilised chicken eggs. On day four 
of embryonic development, a hole was cut in the shells of the eggs. The shell was then 
resealed using sterile sticky tape and the eggs were returned to the incubator until day eight of 
embryonic development. On day eight, CAMs were inoculated with cancer cells. These were 
left to grow until day twelve of embryonic development, when treatment with resveratrol 
commenced. On embryonic development day eighteen, the tumour implants were excised 
from the surrounding CAMs and then fixed at 4oC overnight. 
Fixing solution was removed and replaced with approximately 2 mL 1x PBS. Samples were 
then gently shaken for five minutes to rinse the samples. This rinsing process was repeated 
twice with fresh 1x PBS. 
The CAM around the tumour implants was carefully trimmed using a scalpel blade, then the 
sample was embedded vertically in optimal cutting temperature (OCT) compound (Tissue-
Tek), ensuring that no air bubbles were present in the OCT compound. Samples were frozen 
at -80oC for at least 30 minutes before being transferred to a -20oC freezer for storage. 
2.2.1.2 Frozen sectioning 
 
SuperFrost Plus slides were appropriately labelled using pencil, and a chuck and block were 
placed on dry ice to bring down the temperature so that OCT compound would begin to 
freeze solid on contact. OCT compound was used to securely mount the frozen sample onto 
the chuck, and the sample and chuck were kept on dry ice for several minutes to ensure the 
OCT compound was completely frozen.  
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The sample and chuck were then loaded into a cryostat (Leica) set to -20oC and sectioned. 
Three sections of the tumour implants, each 7 µm thick were placed on each slide, and seven 
slides were collected per frozen sample. Slides were stored at -20oC until needed. 
 
2.2.2 H&E staining 
 
Frozen slides were allowed to dry at 37oC for approximately ten minutes to remove any 
moisture before samples were outlined using a mini PAP pen containing hydrophobic ink 
(ABCAM). 
After the ink had dried completely, samples were covered with approximately 300 µL Harris’ 
haematoxylin and incubated at room temperature for 20 minutes. Slides were rinsed using 
Scott’s tap water until the water ran clear (approximately five times). Slides were then rinsed 
using differentiation buffer five times. The samples were covered with 300 µL Scott’s tap 
water and incubated at room temperature for two minutes. The samples were then covered 
with 300 µL eosin and incubated at room temperature for ten minutes. Slides were rinsed 
using Scott’s tap water until the eosin stopped streaking (approximately three times).  
The samples were then dehydrated by sequentially dipping the slides in 50% ethanol ten 
times, 70% ethanol ten times, then immersing in 95% ethanol for 30 seconds, 100% ethanol 
for one minute, and finally dipped in 100% xylene ten times. Slides were allowed to dry 
completely before a coverslip was mounted using DPX Mountant mounting media. 
2.2.2.1 Counting red blood cells 
 
A micrograph was taken near the centre of each implant using a 10x objective lens (Zeiss; 
numerical aperture: 0.25). The area of the implant visible in the photo was determined using 
Zen software. The red blood cells visible within this area were counted manually, and then 
expressed as a number of red blood cells per mm2. 




Cancer cells located inside the mesodermal region of the CAM of each implant were 
manually counted by observation through a microscope using a 40x objective lens (Zeiss; 
numerical aperture: 0.65). 
 
2.2.3 Immunohistochemical staining 
 
2.2.3.1 Cell cultures 
 
Human cancer cell lines derived from ovarian adenocarcinoma patients, OVCAR-8 and 
SKOV-3, were provided by Dr Chitcholtan. Both cell lines were maintained continuously in 
5 mL working media in 25 mL culture flasks in a 5% CO2 incubator at 37
oC. All subculturing 
and experimental procedures were carried out under sterile conditions in a cell culture 
laminar flow cabinet.  
Working media was replaced with warmed, fresh working media every two to three days. 
Confluency was determined using a light microscope; when cells were 60 – 80% confluent, 
cells were subcultured.  
To subculture, the media was discarded, and the flask was rinsed with sterile 1x PBS. 4 mL 
sterile 1x Trypsin-EDTA was added to the flasks, and flasks were incubated at 37oC for 
approximately 15 – 20 minutes, until no cells remained adhered to the bottom of the flask. 
The contents of the flasks were transferred to centrifuge tubes, and the flasks were rinsed 
with approximately 2 mL sterile 1x PBS, which was also transferred to the centrifuge tubes. 
Cells were centrifuged at 2500 rpm for five minutes. The supernatant was discarded, and the 
cell pellets were resuspended in 5 mL warmed, fresh working media. 1 mL of the resulting 
cell suspension was added to a new culture flask along with 5 mL warmed, fresh working 
media. 
2.2.3.2 Immunohistochemical analysis 
 
The solution used to fix cells and tissue samples was paraformaldehyde, which is a cross-
linking agent. Antibodies may not recognise cross-linked antigens, and so will not necessarily 
bind to their target proteins. This leads to a lack of staining, and so an antigen retrieval step 
was required prior to immunohistochemical analysis in this case. 
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Slides were submerged in approximately 500 mL antigen retrieval buffer, heated to 95oC for 
20 minutes. The temperature of the buffer was monitored during this time: the temperature 
was not allowed to exceed 95oC while the slides were submerged, as rigorous boiling can 
damage samples, and if the temperature dropped below 90oC the samples were temporarily 
removed until the temperature reached 95oC again. 
Slides were allowed to cool and dry completely and were then rinsed five times using wash 
buffer before samples were outlined using hydrophobic ink. 
Membrane permeabilization was required for antibodies to gain access to their target 
antigens. After the ink had dried completely, samples were covered with 300 µL membrane 
permeabilization solution and incubated at room temperature for 20 minutes. Slides were then 
rinsed five times using wash buffer. 
To block endogenous peroxidase activity, samples were covered with approximately 300 µL 
peroxide block. Slides were incubated at room temperature for ten minutes, then rinsed four 
times using wash buffer. 
Samples were then covered with approximately 300 µL protein block. Then, slides were 
incubated at room temperature for ten minutes, and then rinsed twice using wash buffer. 
After protein blocking, samples were covered with approximately 300 µL of the appropriate 
dilution of primary antibody in 4% BSA, and then were incubated at 4oC overnight. To rinse 
samples, slides were submerged in wash buffer, which was agitated using a magnetic stirring 
bar, for 20 minutes. 
Next, samples were covered with approximately 300 µL biotinylated goat anti-polyvalent. 
Slides were incubated at room temperature for ten minutes, then slides were submerged in 
wash buffer with a magnetic stirring bar for 20 minutes. 
Samples were subsequently incubated with approximately 300 µL secondary antibody 
(streptavidin), conjugated to horseradish peroxidase for ten minutes at room temperature, 
then slides were submerged in wash buffer with a magnetic stirring bar for 20 minutes. 
Finally, samples were covered with approximately 300 µL chromogenic AEC single solution. 




Samples were covered with approximately 300 µL haematoxylin. Slides were incubated at 
room temperature for 20 minutes, then rinsed using water until the water ran clear 
(approximately five times). Haematoxylin stains nuclei, and can sometimes overpower 
positive staining of nuclear antigens, including Ki67. For this reason, counterstaining with 
haematoxylin was omitted for this antibody. 
Slides were allowed to dry completely before a coverslip was mounted. The mounting media 
DPX Mountant is suitable for slides stained with haematoxylin and eosin, 
but it was found to be quite harsh and degraded the brown stain that indicated positive 
immunohistochemical staining, which caused the staining to be lost when the coverslip was 
mounted. For this reason, this process was repeated with a milder mounting media, 
ImmunoHistoMount, to facilitate retention of the visible positive stain for analysis. A 
micrograph was taken near the centre of each implant using a 10x objective lens (Zeiss; 
numerical aperture: 0.25) for analysis. 
2.2.3.3 Controls (cell monolayers) 
 
Slides with eight plastic wells affixed were used for controls and optimisation of antibodies. 
Cell monolayers (OVCAR-8, SKOV-3) were grown in each of these wells. 
The protocol for immunohistochemical analysis was the same as described above (2.2.3.2), 
except a serial dilution of primary antibody was used (1/200, 1/400, 1/800), with two wells 
dedicated to each dilution factor to establish the optimum dilution factor of each antibody. 
It was determined that the optimum dilution factor for both the VEGF and Ki67 antibodies 
was 1/200. The optimum dilution factor for the CD31 antibody used was determined by the 
manufacturer as being 1/50. 
Negative controls were incubated overnight at 4oC with 4% BSA only. 
2.2.4 TUNEL assay 
 




Frozen slides were allowed to dry at 37oC to remove any moisture before samples were 
outlined using a mini PAP pen. After the ink had dried completely, samples were covered 
with 300 µL 1x TBS and incubated at room temperature for 15 minutes. 
1 µL Proteinase K solution was mixed with 99 µL water for each slide being analysed. 
Samples were covered with this solution and incubated at room temperature for no longer 
than ten minutes. Slides were then rinsed in 1x TBS for five minutes. 
To block endogenous peroxidase activity, 10 µL 30% hydrogen peroxide was mixed with 90 
µL 100% methanol for each slide being analysed. Samples were covered with this solution 
and incubated at room temperature for five minutes, and then slides were rinsed in 1x TBS 
for five minutes. 
Next, samples were covered with 100 µL Equilibration Buffer and incubated at room 
temperature for 30 minutes. 
To label cells containing fragmented DNA, 1 µL TdT Enzyme solution was mixed with 39 
µL TdT Labelling Reaction Mix for each slide being analysed. Samples were covered with 
this solution and a coverslip was applied. Slides were incubated in a humidified chamber at 
37oC for 90 minutes, following which the coverslips were carefully removed by submerging 
slides in 1x TBS, and then slides were rinsed in 1x TBS for five minutes. 
To stop the labelling reaction, samples were subsequently covered with 100 µL Stop Buffer 
and incubated at room temperature for ten minutes. Slides were then rinsed in 1x TBS for 
five minutes. 
Next, samples were covered with 100 µL Blocking Buffer and incubated at room temperature 
for ten minutes, then slides were rinsed in 1x TBS for five minutes. 
4 µL 25x Conjugate solution was mixed with 96 µL Blocking Buffer for each slide being 
analysed and samples were subsequently covered with this solution and incubated at room 
temperature for 30 minutes.  
For chromogenic labelling of TUNEL-positive cells, 4 µL DAB Solution 1 was mixed with 
116 µL DAB Solution 2 for each slide being analysed. Samples were covered with this 
solution and incubated at room temperature for 15 minutes and were then rinsed in water 
until the water ran clear (approximately three times).  
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Finally, samples were covered with 100 µL Methyl Green Counterstain and incubated at 
room temperature for 20 minutes. Slides were dipped in 100% ethanol four times, and then 
this was repeated with fresh ethanol. Slides were then dipped in 100% xylene four times and 
then allowed to dry completely before a coverslip was mounted using ImmunoHistoMount 
mounting media. 
A micrograph was taken near the centre of each implant using a 10x objective lens (Zeiss; 
numerical aperture: 0.25) for analysis. 
2.2.4.2 Controls (cell monolayers) 
 
Samples were covered with 300 µL 1x TBS and incubated at room temperature for 15 
minutes. 
1 µL Proteinase K solution was mixed with 99 µL 10 mM Tris (pH 7.8) for each slide being 
analysed. Samples were covered with this solution and incubated at room temperature for no 
longer than five minutes. Slides were then dipped in 1x TBS three times. 
The remainder of the protocol was the same as for the frozen sections (above, 2.2.4.1). 
For positive controls, the working media was supplemented with 1 µM paclitaxel. Cells were 
incubated at 37oC for two days to allow cells to grow, and then fixed at 4oC overnight.  
For negative controls, the protocol was the same as for positive controls, except treatment 
with paclitaxel was omitted.  
 
2.2.5 Analysis of images (ImageJ) 
 
2.2.5.1 Samples stained for VEGF 
 
Brightness was adjusted to remove some of the background, then colours were deconvoluted 
to separate haematoxylin staining from AEC staining and noise. The image showing AEC 
staining was then converted to black and white. The region of interest was selected and 
measured, which provided the mean grey value for the selected area. Mean grey values were 
the sum of grey values of all pixels within the selection, divided by the number of pixels. 
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2.2.5.2 Samples stained for Ki67 
 
Brightness was adjusted to remove some of the background, then the background was 
subtracted, and the remaining image was converted to black and white. The region of interest 
was selected and measured, which provided the mean grey value for the selected area. 
2.2.5.3 Samples on which a TUNEL assay was performed 
 
Brightness was adjusted to remove some of the background, then colours were deconvoluted 
to separate methyl green staining from DAB staining and noise. The image showing DAB 
staining was then converted to black and white. The region of interest was selected and 
measured, which provided the mean grey value for the selected area. 
2.2.6 Statistical analysis 
 
Statistical analyses were performed using GraphPad Prism software. Experimental results 
were assessed for significance using a two-tailed t-test and a one-way ANOVA. p < 0.05 was 




3 Results and Discussion 
 
3.1 Morphology of tumour implants grown on CAMs 
 
In order to evaluate the growth of OVCAR-8 and SKOV-3 tumour cells implanted on CAMs, 
the morphology of these tumour implants and their associated vascular networks were 
investigated. 
OVCAR-8 cells were encapsulated in collagen gels and placed on the surface of CAMs. 
Cancer cells were then allowed to grow for six days (Fig. 3.1 and 3.2). The vascular networks 
of the CAMs surrounding the tumour implants are visible (Fig. 3.1), although it is not 
possible to visually distinguish between the control implants (A) and implants treated with 
resveratrol (B – E). The vascular networks underneath the implants are more readily visible 
when the implants have been removed from the surrounding CAM and inverted (Fig. 3.2). 
Again, there are no apparent differences between the control implants (A) and those treated 





Figure 3.1 Stereomicroscopic images of OVCAR-8 tumour implants after 18 days growth 
on CAMs. Tumour implants were treated with various doses of resveratrol for six days, 
starting at day 12 of embryonic development, and then images were taken. Control (A), 0.3 





Figure 3.2 Stereomicroscopic images of excised and inverted OVCAR-8 tumour implants 
after 18 days growth on CAMs. Tumour implants were excised from surrounding CAM and 
inverted so the vascular networks could be viewed from underneath. Control (A), 0.3 µg (B), 
0.5 µg (C), 46 µg (D), 91 µg (E), 183 µg resveratrol (F). Scale bar, 1 mm. 
 
Using the same method utilised for OVCAR-8 cells, SKOV-3 cells captured in collagen gels 
were placed on CAMs and allowed to grow for six days (Fig. 3.3 and 3.4). The vascular 
networks of the CAMs are visible from above (Fig. 3.3), but the control implants (A) show 
no differences compared to those treated with resveratrol (B – E). Again, the vascular 
networks beneath implants are more easily observable when the implants are cut out from the 
surrounding CAM and viewed from underneath (Fig. 3.4). Again, there were no obvious 




Figure 3.3 Stereomicroscopic images of SKOV-3 tumour implants after 18 days growth on 
CAMs. Tumour implants were treated with various doses of resveratrol for six days, starting 
at day 12 of embryonic development, and then images were taken. Control (A), 0.3 µg (B), 




Figure 3.4 Stereomicroscopic images of excised and inverted OVCAR-8 tumour implants 
after 18 days growth on CAMs. Tumour implants were excised from surrounding CAM and 
inverted so the vascular networks could be viewed from underneath. Control (A), 0.3 µg (B), 




3.2 Number of red blood cells found in tumour implants 
 
The number of red blood cells found in the tumour implants is indicative of the degree to 
which angiogenesis has occurred, as more extensive angiogenesis is likely to lead to the 
presence of a greater number of red blood cells. As a result, counting the red blood cells can 
provide an indirect measure of angiogenesis. Staining with haematoxylin and eosin makes red 




Figure 3.5 Microscopic images of tumour implants (OVCAR-8) after six days of treatment 
with varying doses of resveratrol showing red blood cells present in implants (arrows). 
Treatment with 46 µg resveratrol led to reduced numbers of red blood cells in implants (see 
Fig. 3.7). Control (A), 0.3 µg (B), 0.5 µg (C), 46 µg (D), 91 µg (E), 183 µg (F) resveratrol. 




Figure 3.6 Microscopic images of tumour implants (SKOV-3) after six days of treatment 
with varying doses of resveratrol showing red blood cells present in implants (arrows). 
Treatment with 91 µg resveratrol led to reduced numbers of red blood cells in implants (see 
Fig. 3.7). Control (A), 0.3 µg (B), 0.5 µg (C), 46 µg (D), 91 µg (E), 183 µg (F) resveratrol. 




Figure 3.7 Number of red blood cells present in tumour implants (OVCAR-8 (n = 85) and 
SKOV-3 (n = 109)) after six days of treatment with varying doses of resveratrol. Numbers of 
red blood cells were significantly reduced in OVCAR-8 implants treated with 46 µg 
resveratrol, and in SKOV-3 implants treated with 91 µg resveratrol. Data expressed as 
means ± SEM. Data considered statistically significantly compared to controls are indicated 
as p < 0.05 (*). 
 
In OVCAR-8 implants, a significant decrease in the number of red blood cells per mm2 was 
observed when implants were treated with 46 µg resveratrol compared with control implants 
(p < 0.0001, t-test) (Fig. 3.7).  In SKOV-3 implants, treatment with 91 µg resveratrol led to a 
significant decrease in the number of red blood cells present relative to controls (p = 0.0131, 
t-test) (Fig. 3.7).  
These results suggest that, at certain concentrations, resveratrol can lead to the presence of 
significantly fewer red blood cells in tumour implants, possibly due to the inhibition of 
angiogenesis. For both cell lines tested, there seems to be an optimum dose of resveratrol, at 
which a statistically significant reduction in the number of red blood cells present in the 
tumour implants is observed. Doses above or below this optimum dose may have no effect on 
the number of red blood cells present in implants or may increase the number of red blood 
cells. This suggests that while some doses of resveratrol may suppress angiogenesis in these 
tumour implants, some doses of resveratrol may actually support angiogenesis. 
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In the literature, multiple studies describe resveratrol as having an anti-angiogenic effect, 
particularly when it is administered at high doses (Chen & Tseng, 2007). One study using rat 
malignant glioma cells (RT-2) found that treatment with 40 mg/kg/day of resveratrol led to 
reduced micro-vessel density after 21 days of treatment, but not after 14 days of treatment 
(Tseng et al., 2004). This is in contrast to treatment with 10 mg/kg/day of resveratrol, for 
which they observed had no effect on micro-vessel density (Tseng et al., 2004). Another 
study investigating the effect of resveratrol on angiogenesis in human umbilical vein 
endothelial cells found that treatment with 100 or 500 µM resveratrol for 24 hours inhibited 
tube formation, whereas treatment with 10 or 50 µM had no effect (J. C. Wong & Fiscus, 
2015). These results suggest that both dose and exposure time are factors which can impact 
the anti-angiogenic effect of resveratrol. 
An in vivo study using pancreatic cancer (MIA PaCa-2) xenografts in a mouse model 
observed reduced micro-vessel density in mice that had been treated with 40 mg/kg/day 
resveratrol for 28 days compared with controls (Harikumar et al., 2010). A similar study 
using ovarian cancer (PA-1) xenografts in a mouse model found that treatment with 50 or 100 
mg/kg/day resveratrol for 28 days led to a dose-dependent reduction in micro-vessel density 
(Lee et al., 2009). A different research group used the CAM model to investigate the effects 
of resveratrol on angiogenesis and found that the addition of discs containing 25, 50, or 100 
µg resveratrol for 48 to 72 hours induced the formation of avascular zones in the developing 
CAMs (Brakenhielm, Cao, & Cao, 2001). 
The data from the present study are generally in agreement with the literature, as low 
resveratrol doses have varied effects on the number of red blood cells present, whereas the 
optimum dose, which leads to a decrease in red blood cell counts, is a higher dose. However, 
it is not clear why doses higher than the optimum do not lead to reduced red blood cell 
counts. Some research suggests that under some circumstances, resveratrol may actually have 
a pro-angiogenic effect, although this effect is not typically observed in the context of tumour 
angiogenesis (Chen & Tseng, 2007). 
It is worth noting that the number of red blood cells present in tumour implants provides only 
an indirect measure of angiogenesis. Therefore, these data may not provide an accurate 





3.2.1 Immunostaining of CD31 in tumour implants 
 
Immunostaining for proteins that are known to have a role in angiogenesis represents an 
alternative method of quantifying angiogenesis in tumour implants. CD31, or platelet 
endothelial cell adhesion molecule (PECAM)-1, is highly expressed on the surface of 
endothelial cells and its involvement in monitoring vessel density in tumour tissue is well 
established (DeLisser et al., 1997; Schlüter et al., 2018). It is an endothelial cell-cell adhesion 
molecule, and, as angiogenesis involves the destruction and formation of endothelial cell-cell 
interactions and the migration of endothelial cells, CD31 can be used as a marker of 
angiogenesis (DeLisser et al., 1997; Schlüter et al., 2018). 
It is possible that resveratrol exerts its effect on angiogenesis via restriction of the growth and 
migration of endothelial cells. If this were the case, antibody staining for CD31 might have 
provided useful information about the effect of resveratrol on angiogenesis. However, this 
experiment was unsuccessful, perhaps due to improper optimisation of the antibody, 
insufficient affinity of the antibody for CD31, or an error in the experimental protocol, but 
time constraints did not permit further investigation. 
Other studies suggest that CD31 staining can be a good indicator of angiogenesis. A study 
using pancreatic cancer (MIA PaCa-2) xenografts in a mouse model observed 
downregulation of CD31 in mice treated with 40 mg/kg/day resveratrol for 28 days compared 
with controls (Harikumar et al., 2010). It has also been shown that 28 days of treatment with 
50 or 100 mg/kg/day resveratrol reduced CD31 expression in ovarian cancer (PA-1) 




3.3 Immunostaining of vascular endothelial growth factor (VEGF) in tumour 
implants 
 
VEGF is a key mediator of angiogenesis, and cells that express VEGF are therefore likely to 
be actively involved in angiogenesis. An increase in positive staining indicates more VEGF is 
present in the tumour implant, which in turn suggests that more angiogenesis is occurring in 
that implant. VEGF, stained brown, is clearly prevalent in the tumour region of these 





Figure 3.8 Microscopic images of tumour implants (OVCAR-8) after six days treatment 
with various doses of resveratrol showing staining of VEGF (arrows). Treatment with 
resveratrol did not significantly alter VEGF expression in tumour implants (see Fig. 3.10). 




Figure 3.9 Microscopic images of tumour implants (SKOV-3) after six days treatment with 
different doses of resveratrol showing staining of VEGF (arrows). Treatment with 
resveratrol did not significantly alter VEGF expression in tumour implants (see Fig. 3.10). 




Figure 3.10 Intensity of immunohistochemical staining of VEGF in tumour implants 
(OVCAR-8 (n = 58) and SKOV-3 (n = 56)) after six days of treatment with various doses of 
resveratrol. There is no statistically significant difference between control implants and 
implants treated with resveratrol (p > 0.05). Data expressed as means ± SEM. 
These data suggest that treatment with resveratrol did not lead to a significant effect on 
expression of VEGF in tumour implants, irrespective of cell line or resveratrol dose (Fig. 
3.10). Many previous studies have shown that resveratrol is capable of reducing expression of 
VEGF and thereby inhibiting angiogenesis, so it is surprising that the present experiment 
showed no effect of resveratrol on VEGF expression. For example, a study investigating 
VEGF expression in rat glioma cells (RT-2) in response to resveratrol treatment observed that 
treatment with 10, 25, or 100 µM resveratrol for six, 24, or 48 hours led to suppression of 
VEGF expression (Tseng et al., 2004). VEGF expression in the human osteosarcoma cell line 
U20S was also shown to be suppressed when cells were treated with 10, 20, or 40 µM 
resveratrol for 24, 48, or 72 hours (Z. Liu, Li, & Yang, 2012). That study found that 
suppression of VEGF expression increased with increasing doses or resveratrol and 
increasing exposure times (Z. Liu et al., 2012). 
Human retinal pigment epithelial cells treated with 10, 20, or 50 µM resveratrol for 48 hours 
displayed a dose-dependent reduction in VEGF secretion, whereas treatment with 2 µM 
resveratrol for the same time period had no effect (Nagineni et al., 2014). A similar study 
investigated the effects of a wider range of resveratrol doses on human gingival fibroblast 
cells over 48 hours (Núñez et al., 2010). Results showed that 10, 20, 40, 80, or 160 µM 
resveratrol suppressed VEGF in a dose-dependent manner (Núñez et al., 2010). In addition, 
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an in vivo study using human bladder cancer (T24) xenografts in a mouse model observed 
suppression of VEGF expression in mice treated with 20 mg/kg/day resveratrol for 28 days 
compared with controls (Bai et al., 2010). 
Several in vitro experiments have used ovarian cancer cells to study the effects of resveratrol 
on VEGF expression. One treated A2780/CIP and OVCAR-3 cells with 12.5 – 150 µM 
resveratrol for six hours and observed dose-dependent inhibition of VEGF (Cao, Fang, Xia, 
Shi, & Jiang, 2004). Another tested the effects of treatment of OVCAR-3 and Caov-3 cells 
with 10, 25, or 50 µM resveratrol for 24 hours, and also found that resveratrol suppressed 
VEGF in a dose-dependent fashion (Park et al., 2007). Furthermore, an in vivo study using 
mice bearing Ehrlich ascites carcinoma found that treatment with 10 mg/kg/day resveratrol 
for seven days led to a significant inhibition of VEGF (El-Azab, Hishe, Moustafa, & El-
Awady, 2011) 
The results of the present study may suggest that these doses of resveratrol have no 
significant effect on angiogenesis in tumour implants grown using the CAM model. 
However, this is inconsistent with the results of the above experiment in which the number of 
red blood cells were reduced by some doses of resveratrol. It also seems unlikely that 
resveratrol has no effect on angiogenesis given the wealth of previous research indicating that 
resveratrol can inhibit VEGF expression and angiogenesis. It is possible that the mechanism 
of angiogenesis occurs somewhat differently in the CAM model with respect to VEGF 
expression. While VEGF is typically known to be important with respect to angiogenesis, it is 
not the only protein to play role in this process. (Hu et al., 2018). 
Previous research has suggested that the effect of resveratrol on angiogenesis – whether it 
exerts a pro- or anti-angiogenic effect – may be determined by the situation (Chen & Tseng, 
2007). Generally, in the context of tumour angiogenesis, resveratrol has been shown to have 
an anti-angiogenic effect; however, in some situations, resveratrol may support angiogenesis 
(Chen & Tseng, 2007; Trapp, Parmakhtiar, Papazian, Willmott, & Fruehauf, 2010). The exact 
reasons why resveratrol can behave differently under different circumstances are not 
understood, however dosage, pharmacokinetics, events, and cell types are factors that are 
worth considering (Chen & Tseng, 2007). 
In the literature, data from experiments involving low doses (up to approximately 1.5 
mg/kg/day) of resveratrol are inconsistent (Chen & Tseng, 2007; J. C. Wong & Fiscus, 2015). 
It is therefore possible that the doses of resveratrol administered in this experiment may not 
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be sufficient to exert an anti-angiogenic effect. In addition, a well-described clinical 
shortcoming of resveratrol is its poor bioavailability (Berman, Motechin, Wiesenfeld, & 
Holz, 2017; Tino, Chitcholtan, Sykes, & Garrill, 2016). Resveratrol is rapidly metabolised, 
primarily via glucuronidation and sulphation, giving it a short initial half-life, and the extent 
to which metabolites retain the activity of the parent molecule is currently unclear (Berman et 
al., 2017; Chen & Tseng, 2007). Resveratrol metabolites may not have as pronounced an 




3.4 Invasion of tumour cells into the CAM  
 
Tumour cell invasion is indicative of the aggressiveness of tumour cells. Ovarian cancer cells 
often grow on the surface of the peritoneal membrane in the form of tumour nodules early 
during metastasis, and some cancer cells can invade through this membrane and into distant 
tissues. Consequently, patients with invasive tumour cells typically have poor prognoses. 
The CAM model facilitates investigation into the invasiveness of tumour cells and 
assessment of the effect of resveratrol on this invasiveness. The number of cancer cells found 
inside the mesodermal layer of the CAM is reflective of the invasiveness of those cancer 
cells. Staining with haematoxylin and eosin colours cancer cells intensely purple, making 




Figure 3.11 Microscopic images of tumour implants (OVCAR-8) after six days treatment 
with varying doses of resveratrol showing invasion of cancer cells into the mesodermal 
layer of CAMs (CAM area is indicated by arrows). Treatment with 91 µg resveratrol led to 
reduced invasion of tumour cells into the CAM (see Fig. 3.13). Control (A), 0.3 µg (B), 0.5 




Figure 3.12 Microscopic images of tumour implants (SKOV-3) after six days treatment 
with varying doses of resveratrol showing invasion of cancer cells into the mesodermal 
layer of CAMs (arrows). Treatment with 91 µg resveratrol led to reduced invasion of tumour 
cells into the CAM (see Fig. 3.13). Control (A), 0.3 µg (B), 0.5 µg (C), 46 µg (D), 91 µg (E), 




Figure 3.13 Number of invasive cancer cells present inside the CAM tissue from the 
tumour implants (OVCAR-8 (n = 83) and SKOV-3 (n = 92)), which were treated with 
various doses of resveratrol for six days. Numbers of invasive cancer cells were significantly 
reduced in both OVCAR-8 and SKOV-3 implants treated with 91 µg resveratrol. Data 
expressed as means ± SEM. Data considered statistically significantly compared to controls 
are indicated as p < 0.05 (*). 
 
In both OVCAR-8 and SKOV-3 implants, treatment with 91 µg resveratrol led to 
significantly fewer cancer cells inside the mesodermal region of the CAM compared with 
control implants (p = 0.0066 and 0.0014 respectively, t-test) (Fig. 3.13). These results suggest 
that, at certain concentrations, resveratrol can lead to the inhibition of cancer cell migration 
and invasion. For both OVCAR-8 and SKOV-3, 91 µg resveratrol appears to be the optimum 
dose, and doses above or below this do not affect the invasive capability of tumour cells. 
In the literature, it has been reported that resveratrol can inhibit migration and invasion of 
tumour cells and inhibit metastasis. One research group that carried out wound healing assays 
using human renal cell carcinoma cells (ACHN, A498) observed a reduction in movement of 
cells treated with 100 µM resveratrol for 24 hours compared with controls (Zhao, Tang, 
Zeng, Ye, & Liu, 2018). Another group carried out a similar wound healing assay, this time 
using cervical cancer (HeLa) and lung adenocarcinoma (A549) cells; this study found that 
treatment with 30 µM resveratrol for 24 hours led to reduced cell migration (Y. S. Kim, Sull, 
& Sung, 2012). 
74 
 
Treatment with 25, 50, 100, 200, 400, or 800 µM resveratrol for 72 hours also resulted in less 
migration in wound healing assays performed on ovarian cancer cells (A2780, SKOV-3) (Y. 
Liu et al., 2018). Invasion of ovarian cancer cells (NuTu-19) across a Matrigel membrane 
was shown to be inhibited in cells treated with 100 µM resveratrol for 48 hours compared 
with controls (Stakleff et al., 2012). Furthermore, an  in vivo study using ovarian cancer 
(SKOV-3) xenografts in a mouse model resulted in a reduced metastatic index in mice treated 
with 100 mg/kg/day resveratrol for 18 days compared with control mice (Y. Liu et al., 2018). 
Inhibition of cell migration and invasion by resveratrol could be mediated by a wide variety 
of proteins. MMPs including MMP-2, 7, and 9 are involved in degradation of the ECM, 
which is required for EMT and migration, and so are possible targets. Treatment of HeLa and 
A549 cancer cells with 10 or 30 µM resveratrol for 24 hours led to reduced expression of 
MMP-9 (Y. S. Kim et al., 2012). 15, 30, or 50 µM resveratrol suppressed MMP-7 expression 
in human colorectal cancer cells (LoVo, HCT116) in a dose-dependent manner over a time 
period of 24 or 48 hours (Ji et al., 2013). Expression of both MMP-2 and MMP-9 was shown 
to decrease in renal cell carcinoma cells (ACHN, A498) in response to treatment with 10, 20, 
50, 100, and 200 µM resveratrol for 24 hours, and, again, this effect was dose-dependent 
(Zhao et al., 2018). 
Cell adhesion molecules also represent a possible target as the dissolution and reformation of 
endothelial cell-cell interactions is involved in cell migration (Lamouille et al., 2014). An 
investigation into the effects of 24 hours of treatment with 10, 20, 50, 100, and 200 µM 
resveratrol on renal cell carcinoma cells (ACHN, A498) demonstrated a reduction in 
expression of N-cadherin as well as the transcriptional repressor Snail, along with a 
corresponding increase in E-cadherin expression (Zhao et al., 2018). 
Signal transduction pathways, such as the PI-3K/Akt and ERK1/2 pathway, are involved in 
regulating cell migration and invasion, among other things, and so represent another potential 
target of cell invasion inhibitors; this is supported by the decreased expression of p-Akt and 
p-ERK1/2 observed in ACHN and A498 cells treated with between 10 and 200 µM 




3.5 Immunostaining of Ki67 in tumour implants  
 
Ki67 is present during all active phases of the cell cycle (G1, S, G2, M) but is absent from 
senescent cells (G0), which makes it a useful marker of cellular proliferation (Scholzen & 
Gerdes, 2000). Increased staining, leading to higher mean grey values, is indicative of higher 
levels of Ki67 expression and therefore more cellular proliferation. 
 
Figure 3.14 Microscopic images of tumour implants (OVCAR-8) after six days treatment 
with different doses of resveratrol showing staining of Ki67. Treatment with resveratrol did 
not significantly alter Ki67 expression in tumour implants (see Fig. 3.16). Control (A), 0.3 µg 




Figure 3.15 Microscopic images of tumour implants (SKOV-3) after six days treatment 
with various doses of resveratrol showing staining of Ki67. Treatment with resveratrol did 
not significantly alter Ki67 expression in tumour implants (see Fig. 3.16). Control (A), 0.3 µg 





Figure 3.16 Intensity of immunohistochemical staining of Ki67 in tumour implants 
(OVCAR-8 (n = 60) and SKOV-3 (n = 55)) after six days of treatment with various doses of 
resveratrol. There is no statistically significant difference between control implants and 
implants treated with resveratrol (p > 0.05). Data expressed as means ± SEM. 
These data suggest that the treatment of tumour implants with various doses of resveratrol 
does not affect the expression of Ki67 in OVCAR-8 or SKOV-3 tumour implants (p > 0.05, t-
test) (Fig. 3.16). These results may suggest that these cancer cells are not actively 
proliferating. However, in contrast with the findings of the present study, existing research 
typically shows that resveratrol is able to inhibit proliferation and decrease expression of 
Ki67 (Harikumar et al., 2010; Zhai et al., 2016). 
One study used human breast cancer cells (MCF-7) to investigate the effects of resveratrol on 
cell growth and proliferation, focusing specifically on regulators of the cell cycle (Y. A. Kim 
et al., 2004). That study demonstrated a dose-dependent inhibition of cell growth by 
resveratrol, which was likely a consequence of the inhibition of cyclin D and the associated 
Cdk 4, as well as the induction of p53 and a Cdk inhibitor protein (p21WAF1/CIP) causing 
cells to stall at the G1/S phase transition (Y. A. Kim et al., 2004).  
Pancreatic cancer (MIA PaCa-2) xenografts in a mouse model treated with 40 mg/kg/day 
resveratrol for 28 days showed reduced tumour growth and inhibition of Ki67 expression 
compared with controls (Harikumar et al., 2010). Treatment of ovarian cancer (SKOV-3) 
xenografts in mice with 100 mg/kg/day resveratrol for 18 days was also shown to result in 
smaller tumours and lower Ki67 indices compared with controls (Y. Liu et al., 2018). 
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Given the existing evidence that resveratrol can disrupt proliferation of cancer, it seems 
unlikely that resveratrol has no effect on proliferation; it is more likely that in this particular 
experiment, the lack of effect of resveratrol on proliferation may be due to technical or 
experimental difficulties. It is possible, for example, that the antibody used to detect Ki67 
was not sufficiently specific or was not appropriately optimised for this experiment. Another 
possibility is that the Ki67 antibody used was no longer fully functional, and therefore needed 




3.6 TUNEL assay of tumour implants  
 
Extensive DNA damage can be used as a surrogate marker for apoptosis. More DNA damage 
leads to increased dark brown staining, which is indicative of more apoptosis occurring in 
tumour implants. 
 
Figure 3.17 Microscopic images of tumour implants (OVCAR-8) after six days treatment 
with various doses of resveratrol showing staining of cells containing extensive DNA 
damage (arrows), indicative of apoptosis. Treatment with resveratrol did not increase levels 
of apoptosis occurring in tumour implants (see Fig. 3.19). Control (A), 46 µg (B), 183 µg (C) 
resveratrol. Scale bar, 200 µm. 
 
 
Figure 3.18 Microscopic images of tumour implants (SKOV-3) after six days treatment 
with varying doses of resveratrol showing staining of cells containing extensive DNA 
damage (arrows), indicative of apoptosis. Treatment with resveratrol did not increase levels 
of apoptosis occurring in tumour implants (see Fig. 3.19). Control (A), 91 µg (B), 183 µg (C) 




Figure 3.19 Intensity of staining for DNA damage in tumour implants (OVCAR-8 (n = 47) 
and SKOV-3 (n = 37)) after six days of treatment with varying doses of resveratrol. 
Treatment with resveratrol did not lead to a significant increase in DNA damage in tumour 
implants. Data expressed as means ± SEM. Data considered statistically significantly 
compared to controls or other doses are indicated as p < 0.05 (*). 
In OVCAR-8 implants, treatment with 46 µg resveratrol did not lead to a significant increase 
in the amount of DNA damage present (p > 0.05, t-test), although there appears to be a trend 
for an increase in DNA damage with 46 µg resveratrol, but due to the small sample size and 
high variability of the results, this was not statistically significant (Fig. 3.19). Somewhat 
paradoxically, treatment of implants with 183 µg resveratrol led to a significant decrease in 
DNA degradation compared to control implants (p = 0.0022, t-test) and implants treated with 
46 µg resveratrol (p = 0.0039, t-test).  
In SKOV-3 implants, treatment with 91 µg resveratrol did not lead to an increase in DNA 
damage (p > 0.05, t-test) (Fig. 3.19). Again, a trend for an increase in DNA damage with 91 
µg resveratrol may be present but this was not statistically significant. Interestingly, 
compared with implants treated with 91 µg resveratrol, treatment with 183 µg resveratrol led 
to a significant decrease in DNA damage (p = 0.0074, t-test), but there was no statistically 
significant difference between the DNA damage in control implants compared to those 
treated with 183 µg resveratrol (p > 0.05, t-test). 
Existing research suggests that treatment with resveratrol can lead to increased apoptosis, 
although the extent of this pro-apoptotic effect may vary significantly depending on the cell 
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line used (Takashina et al., 2017). Evidence suggests that resveratrol is capable of activating 
the intrinsic, or mitochondrial, apoptotic pathway by depolarising the mitochondrial 
membrane, thereby facilitating the secretion of cytochrome c into the cytosol and the 
subsequent activation of caspases 9 and 3 (Sareen et al., 2006). It may also stimulate 
apoptosis by disturbing the balance of pro- and anti-apoptotic proteins present in cells 
(Benitez, Pozo-Guisado, Alvarez-Barrientos, Fernandez-Salguero, & Castellon, 2007). 
Treatment with resveratrol has been shown to lead to downregulation of anti-apoptotic 
proteins such as Bcl-2 and Bcl-XL, and upregulation of pro-apoptotic proteins such as Bax 
and Bak (Benitez et al., 2007; Sareen et al., 2006).  
Treatment of ovarian cancer cells (PA-1) with 50 or 100 µM resveratrol over twelve, 24, or 
48 hours was shown to induce DNA fragmentation, proteolytic activation of caspases 3, 7, 
and 9, and lead to increased activity of caspase-3 (Lee et al., 2009). A similar study 
investigating the effects of treatment with 30 or 100 µM resveratrol for 48 hours in ovarian 
cancer cells (OVCAR-3, Caov-3) showed that resveratrol treatment led to a loss of cell 
viability and the induction of apoptosis, indicated by increased caspase-3 activity (Lang et al., 
2015). In addition, an in vivo study involving ovarian cancer (PA-1) xenografts in a mouse 
model found that treatment with 50 or 100 mg/kg/day resveratrol for 28 days induced 
apoptosis, as indicated by increased TUNEL positivity and caspase-3 staining (Lee et al., 
2009). 
Results of TUNEL assays must be interpreted with caution, as cellular processes other than 
apoptosis, such as necrosis, may also lead to the kind of DNA fragmentation that TUNEL 
assays label (Takashina et al., 2017). However, other researchers have detected an increase in 
apoptotic cells in samples treated with resveratrol using different methods in addition to 
TUNEL assays, such as Annexin V staining, Hoechst staining, accumulation of reactive 
oxygen species, and activity of caspase proteins (Juan, Wenzel, Daniel, & Planas, 2008; Lang 
et al., 2015; Takashina et al., 2017). Therefore, it seems logical to conclude that treatment 






The high morbidity associated with ovarian cancer is due, in part, to a lack of early detection. 
This type of cancer is highly metastatic, with a unique mode of spreading throughout the 
peritoneal cavity. Treatment strategies are harsh, and their efficacy against advanced stage 
disease is limited, as acquired resistance to chemotherapeutic agents is common in advanced 
ovarian cancer. The development of more effective treatments for advanced ovarian cancer 
that offer an alternative to current treatment strategies is therefore an important goal. 
Resveratrol is a compound that occurs naturally in some foods which has been shown to have 
some anti-tumour properties. 
This study investigated the usefulness of the CAM model as a means of replicating the early 
stages of ovarian cancer metastasis, in which tumour nodules develop on the surface of the 
peritoneum. Tumour implants grew well using this model, and this provided a useful platform 
for investigating the effects of resveratrol on the progression of those tumour implants. This 
suggests that the CAM model may be useful for investigations into the efficacy of other anti-
tumour compounds against advanced ovarian cancer. 
This experiment showed that resveratrol treatment may be able to inhibit invasion of tumour 
cells, and some data indicates that resveratrol may be capable of inhibiting angiogenesis. 
However, contrary to the majority of previous research, this study did not demonstrate any 
effect of resveratrol on the proliferation or survival of cancer cells.  
 
4.1 Future research 
 
Resveratrol has been shown to be effective in reducing the growth and progression of various 
cancers, including ovarian cancer, using both cell culture studies and mammalian models. 
Previous research has demonstrated that resveratrol can inhibit angiogenesis, invasion, and 
proliferation, and induce apoptosis in cancer cells. Therefore, further investigation into why 
resveratrol treatment affected only some of these processes in this experiment is warranted.  
One possibility is that the dose of resveratrol used was too low to have any effect. Resveratrol 
is known to have low bioavailability, so it is possible that a very high dose is required. 
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Another avenue worth investigating would be the development of a more metabolically stable 
analogue of resveratrol which exerts similar effects, so that a lower dose is required. 
Another possible explanation is that the exposure time used in this experiment was too short 
for resveratrol treatment to elicit some of its usual effects. The CAM model is limiting in this 
aspect, as embryonic development of chickens takes approximately three weeks, after which 
the eggs will hatch.  
It is also worth considering the possibility that experimental errors occurred during this study, 
and time constraints did not permit further investigation into this possibility. For example, it 
is possible that the Ki67 antibody used needed to be replaced with fresh stock as it was 
possibly no longer functional.  
Finally, as the effects of resveratrol are cell line-specific, testing of resveratrol on a wider 
range of cell lines is necessary. In this study, resveratrol was tested on one high grade serous 
ovarian cancer cell line (OVCAR-8) and one ovarian cancer cell line that is now considered 
unlikely to be of the high-grade serous subtype (Domcke et al., 2013). Investigating the 
effects of resveratrol on more cell lines that represent the high-grade serous subtype, such as 
Caov-3 or OVCAR-3, would be beneficial, as this is the most common ovarian cancer 
subtype (Domcke et al., 2013). It would also be useful to investigate the effects of resveratrol 
on other subtypes, including the endometrioid (Caov-3, Ishikawa), clear cell (Caki-3, ACC-
OV614), and mucinous (MCAS, INT.Ov3) subtypes, as this information would indicate the 
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Figure A1. Optimisation of anti-VEGF staining on OVCAR-8 cell monolayers. Negative 
control (A), positive control (B). Scale bar, 100 µm. 
 
 
Figure A2. Optimisation of anti-VEGF staining on SKOV-3 cell monolayers. Negative 




Figure A3. Optimisation of anti-Ki67 staining on OVCAR-8 cell monolayers. Negative 
control (A), positive control (B). Scale bar, 100 µm. 
 
 
Figure A4. Optimisation of anti-Ki67 staining on SKOV-3 cell monolayers. Negative 




Figure A5. Optimisation of TUNEL assay on OVCAR-8 cell monolayers. Negative control 
(A), positive control (B). Scale bar, 100 µm. 
 
 
Figure A6. Optimisation of TUNEL assay on SKOV-3 cell monolayers. Negative control 




Table A1. Raw data for red blood cell counts and invasion of cancer cells into CAM area 
























04/01/2015 91 µg 649,620 0.6496 11 17 8 
04/01/2015 91 µg 1,023,971 1.0240 13 13 5 
04/01/2015 Control 813,004 0.8130 33 41 10 
01/11/2015 46 µg 973,568 0.9736 23 24 15 
01/11/2015 46 µg 950,620 0.9506 9 9 25 
01/11/2015 91 µg 585,531 0.5855 22 38 6 
01/11/2015 0.5 µg 638,438 0.6384 25 39 45 
01/11/2015 0.5 µg 766,206 0.7662 21 27 35 
01/11/2015 91 µg 621,291 0.6213 27 43 14 
01/11/2015 91 µg 815,950 0.8160 37 45 16 
01/11/2015 91 µg 805,003 0.8050 25 31 22 
01/11/2015 0.5 µg 597,053 0.5971 97 162 
 
01/11/2015 0.5 µg 687,664 0.6877 15 22 12 
18/01/2016 91 µg 487,423 0.4874 44 90 8 
18/01/2016 91 µg 504,499 0.5045 27 54 3 
18/01/2016 91 µg 876,856 0.8769 55 63 8 
18/01/2016 0.3 µg 388,054 0.3881 33 85 8 
18/01/2016 0.3 µg 578,994 0.5790 26 45 10 
18/01/2016 Control 171,551 0.1716 12 70 10 
18/01/2016 Control 455,706 0.4557 17 37 
 
18/01/2016 Control 769,307 0.7693 34 44 6 
18/01/2016 91 µg 436,628 0.4366 18 41 4 
18/01/2016 91 µg 423,878 0.4239 15 35 6 
18/01/2016 91 µg 512,449 0.5124 13 25 10 
99 
 
18/01/2016 0.3 µg 236,601 0.2366 4 17 5 
18/01/2016 0.3 µg 456,139 0.4561 24 53 10 
18/01/2016 0.3 µg 500,237 0.5002 14 28 12 
01/12/2017 0.5 µg 1,143,375 1.1434 19 17 14 
01/12/2017 0.5 µg 1,069,327 1.0693 42 39 32 
01/12/2017 Control 601,937 0.6019 29 48 8 
01/12/2017 Control 649,666 0.6497 60 92 10 
01/12/2017 Control 849,434 0.8494 35 41 25 
01/12/2017 0.5 µg 1,145,960 1.1460 56 49 12 
01/12/2017 0.5 µg 1,112,380 1.1124 12 11 10 
01/12/2017 0.5 µg 1,152,008 1.1520 34 30 16 
01/12/2017 Control 596,714 0.5967 33 55 15 
01/12/2017 Control 736,734 0.7367 61 83 25 
10/10/2018 183 µg 624,018 0.6240 10 16 20 
10/10/2018 183 µg 848,221 0.8482 12 14 25 
10/10/2018 Control 347,804 0.3478 50 144 6 
10/10/2018 Control 592,402 0.5924 8 14 12 
10/10/2018 Control 852,250 0.8523 20 23 15 
10/10/2018 183 µg 703,972 0.7040 28 40 10 
10/10/2018 183 µg 1,210,532 1.2105 70 58 12 
10/10/2018 183 µg 859,006 0.8590 55 64 20 
10/10/2018 183 µg 930,978 0.9310 24 26 20 
10/10/2018 183 µg 970,759 0.9708 12 12 25 
19/10/2018 183 µg 757,241 0.7572 55 73 12 
19/10/2018 183 µg 642,405 0.6424 50 78 15 
19/10/2018 183 µg 697,070 0.6971 75 108 12 
19/10/2018 Control 186,416 0.1864 5 27 26 
19/10/2018 Control 578,772 0.5788 24 41 18 
19/10/2018 Control 461,602 0.4616 22 48 35 
19/10/2018 46 µg 726,779 0.7268 21 29 10 
19/10/2018 46 µg 855,489 0.8555 15 18 10 
19/10/2018 46 µg 700,268 0.7003 15 21 15 
100 
 
19/10/2018 91 µg 511,046 0.5110 7 14 10 
19/10/2018 91 µg 903,341 0.9033 10 11 10 
19/10/2018 91 µg 596,707 0.5967 15 25 12 
19/10/2018 183 µg 605,695 0.6057 10 17 15 
19/10/2018 183 µg 758,666 0.7587 30 40 20 
19/10/2018 183 µg 932,667 0.9327 18 19 12 
19/10/2018 Control 840,742 0.8407 36 43 5 
19/10/2018 Control 748,381 0.7484 45 60 15 
19/10/2018 Control 851,143 0.8511 45 53 15 
19/10/2018 46 µg 864,338 0.8643 18 21 8 
19/10/2018 46 µg 1,102,911 1.1029 12 11 32 
19/10/2018 46 µg 1,055,368 1.0554 25 24 35 
19/10/2018 91 µg 388,419 0.3884 10 26 12 
19/10/2018 91 µg 530,305 0.5303 6 11 10 
19/10/2018 91 µg 493,027 0.4930 8 16 16 
19/10/2018 183 µg 627,623 0.6276 20 32 15 
19/10/2018 183 µg 590,501 0.5905 18 30 25 
19/10/2018 183 µg 639,448 0.6394 10 16 10 
19/10/2018 Control 719,096 0.7191 42 58 12 
19/10/2018 Control 627,131 0.6271 42 67 15 
19/10/2018 Control 866,711 0.8667 35 40 20 
19/10/2018 Control 645,566 0.6456 8 12 15 
19/10/2018 Control 667,319 0.6673 22 33 15 
19/10/2018 Control 794,727 0.7947 15 19 25 
11/11/2018 46 µg 514,645 0.5146 28 54 8 
11/11/2018 46 µg 592,573 0.5926 19 32 11 
11/11/2018 46 µg 653,024 0.6530 10 15 7 
11/11/2018 46 µg 644,496 0.6445 10 16 9 





Table A2. Raw data for red blood cell counts and invasion of cancer cells into CAM area 

























30/03/2015 0.3 µg 1,027,044 1.0270 370 360 
 
30/03/2015 0.3 µg 1,204,253 1.2043 270 224 25 
20/04/2015 Control 1,160,161 1.1602 52 45 
 
20/04/2015 0.5 µg 279,502 0.2795 11 39 
 
20/04/2015 0.5 µg 773,384 0.7734 175 226 
 
20/04/2015 0.5 µg 951,407 0.9514 89 94 
 
10/10/2015 46 µg 757,849 0.7578 56 74 
 
10/10/2015 46 µg 1,117,754 1.1178 74 66 
 
10/10/2015 46 µg 1,145,938 1.1459 68 59 
 
10/10/2015 91 µg 765,109 0.7651 26 34 7 
10/10/2015 91 µg 1,046,802 1.0468 38 36 15 
10/10/2015 91 µg 1,059,625 1.0596 42 40 15 
28/11/2015 46 µg 855,428 0.8554 28 33 15 
28/11/2015 46 µg 1,137,474 1.1375 37 33 8 
28/11/2015 46 µg 1,207,701 1.2077 97 80 5 
28/11/2015 91 µg 653,732 0.6537 29 44 6 
28/11/2015 91 µg 1,172,451 1.1725 26 22 12 
28/11/2015 0.3 µg 257,659 0.2577 18 70 8 
28/11/2015 0.3 µg 535,618 0.5356 14 26 10 
28/11/2015 0.3 µg 594,446 0.5944 84 141 9 
28/11/2015 Control 768,887 0.7689 28 36 8 
28/11/2015 Control 1,224,578 1.2246 73 60 8 
28/11/2015 Control 1,242,308 1.2423 51 41 30 
102 
 
19/03/2016 183 µg 823,091 0.8231 38 46 20 
19/03/2016 183 µg 1,010,131 1.0101 73 72 30 
19/03/2016 183 µg 661,493 0.6615 34 51 15 
19/03/2016 Control 419,083 0.4191 14 33 8 
19/03/2016 Control 445,002 0.4450 12 27 5 
19/03/2016 Control 471,148 0.4711 25 53 10 
19/03/2016 183 µg 859,464 0.8595 138 161 15 
19/03/2016 183 µg 728,773 0.7288 105 144 20 
19/03/2016 183 µg 1,029,516 1.0295 95 92 15 
19/03/2016 Control 176,811 0.1768 32 181 
 
19/03/2016 Control 238,385 0.2384 24 101 
 
19/03/2016 Control 290,836 0.2908 61 210 
 
19/03/2016 183 µg 558,163 0.5582 24 43 5 
19/03/2016 183 µg 624,782 0.6248 35 56 15 
19/03/2016 183 µg 531,482 0.5315 10 19 15 
19/03/2016 183 µg 815,179 0.8152 38 47 10 
19/03/2016 183 µg 746,354 0.7464 67 90 10 
19/03/2016 183 µg 830,501 0.8305 47 57 15 
21/08/2017 183 µg 555,740 0.5557 11 20 8 
21/08/2017 183 µg 760,877 0.7609 19 25 18 
21/08/2017 Control 646,173 0.6462 44 68 6 
21/08/2017 Control 741,983 0.7420 34 46 12 
21/08/2017 Control 570,121 0.5701 60 105 16 
21/08/2017 Control 1,002,637 1.0026 94 94 10 
21/08/2017 Control 1,029,171 1.0292 98 95 5 
21/08/2017 Control 994,452 0.9945 73 73 12 
21/08/2017 183 µg 745,715 0.7457 39 52 25 
21/08/2017 183 µg 726,392 0.7264 70 96 25 
21/08/2017 183 µg 841,947 0.8419 47 56 30 
21/08/2017 183 µg 565,351 0.5654 37 65 12 
21/08/2017 183 µg 873,421 0.8734 41 47 15 
21/08/2017 183 µg 817,204 0.8172 71 87 25 
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21/08/2017 183 µg 928,560 0.9286 54 58 24 
21/08/2017 183 µg 761,455 0.7615 31 41 20 
14/09/2017 0.3 µg 363,146 0.3631 62 171 15 
14/09/2017 0.3 µg 625,829 0.6258 47 75 20 
14/09/2017 0.3 µg 479,477 0.4795 50 104 30 
14/09/2017 0.5 µg 788,884 0.7889 48 61 15 
14/09/2017 0.5 µg 1,113,168 1.1132 55 49 20 
14/09/2017 0.5 µg 1,210,398 1.2104 49 40 10 
14/09/2017 Control 1,148,907 1.1489 58 50 
 
14/09/2017 Control 1,139,731 1.1397 68 60 15 
14/09/2017 Control 891,057 0.8911 64 72 20 
14/09/2017 0.5 µg 920,000 0.9200 82 89 8 
14/09/2017 0.5 µg 967,346 0.9673 41 42 10 
14/09/2017 0.5 µg 1,148,778 1.1488 37 32 15 
14/09/2017 0.5 µg 1,203,314 1.2033 85 71 
 
14/09/2017 0.5 µg 648,899 0.6489 84 129 15 
14/09/2017 0.5 µg 1,159,255 1.1593 88 76 10 
07/02/2018 183 µg 619,766 0.6198 42 68 7 
07/02/2018 183 µg 1,034,832 1.0348 45 43 20 
07/02/2018 183 µg 1,053,451 1.0535 41 39 15 
07/02/2018 Control 1,213,937 1.2139 8 7 30 
07/02/2018 Control 1,057,518 1.0575 98 93 30 
07/02/2018 183 µg 271,020 0.2710 28 103 10 
07/02/2018 183 µg 401,268 0.4013 37 92 
 
07/02/2018 183 µg 582,098 0.5821 16 27 
 
01/09/2018 91 µg 822,599 0.8226 68 83 5 
01/09/2018 91 µg 1,115,168 1.1152 50 45 12 
01/09/2018 Control 447,431 0.447 125 279 14 
01/09/2018 Control 597,131 0.5971 65 109 20 
01/09/2018 Control 722,937 0.723 28 39 30 
01/09/2018 91 µg 275,747 0.2757 14 51 6 
01/09/2018 91 µg 766,644 0.7666 20 26 8 
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01/09/2018 91 µg 952,232 0.9522 25 26 10 
09/09/2018 46 µg 494,013 0.4940 35 71 25 
09/09/2018 46 µg 544,979 0.5450 14 26 30 
09/09/2018 46 µg 583,271 0.5833 34 58 24 
09/09/2018 91 µg 451,731 0.4517 18 40 5 
09/09/2018 91 µg 560,127 0.5601 15 27 6 
09/09/2018 91 µg 523,491 0.5235 20 38 8 
09/09/2018 Control 531,139 0.5311 12 23 10 
09/09/2018 Control 794,989 0.7950 10 13 12 
09/09/2018 Control 979,203 0.9792 20 20 28 
09/09/2018 91 µg 277,799 0.2778 2 7 
 
09/09/2018 91 µg 477,624 0.4776 5 10 
 
09/09/2018 91 µg 520,311 0.5203 10 19 2 
09/09/2018 Control 477,082 0.4771 35 73 5 
09/09/2018 Control 651,562 0.6516 65 100 15 
09/09/2018 Control 548,071 0.5481 80 146 30 
09/09/2018 91 µg 179,589 0.1796 48 267 2 
09/09/2018 91 µg 416,622 0.4166 32 77 8 
09/09/2018 91 µg 527,592 0.5276 20 38 6 
09/09/2018 Control 547,211 0.5472 44 80 12 
09/09/2018 Control 655,292 0.6553 28 43 22 





Table A3. Raw data for mean grey values of OVCAR-8 implants stained for VEGF. 
Experiment 
Date 
Treatment Area (pixel2) Integrated 
density 
Mean grey value 
01/11/2015 46 µg 5,183,048 211,295,040 40.8 
01/11/2015 46 µg 4,308,794 324,826,650 75.4 
01/11/2015 46 µg 4,550,611 308,999,565 67.9 
01/11/2015 Control 4,614,272 288,981,300 62.6 
01/11/2015 Control 4,355,156 340,659,855 78.2 
01/11/2015 Control 5,297,577 375,743,010 70.9 
18/01/2016 0.3 µg 2,876,410 128,617,665 44.7 
18/01/2016 0.3 µg 883,073 145,987,245 165.3 
18/01/2016 0.3 µg 3,219,284 391,270,725 121.5 
18/01/2016 0.3 µg 2,812,385 88,626,780 31.5 
18/01/2016 0.3 µg 4,729,369 360,493,500 76.2 
18/01/2016 0.3 µg 2,319,653 172,161,720 74.2 
18/01/2016 0.3 µg 3,160,317 121,886,430 38.6 
01/12/2017 Control 3,723,786 332,133,930 89.2 
01/12/2017 Control 5,215,618 452,358,780 86.7 
01/12/2017 Control 5,308,321 425,081,685 80.1 
10/10/2018 183 µg 2,196,835 79,609,470 36.2 
10/10/2018 183 µg 4,058,568 47,285,415 11.7 
10/10/2018 183 µg 4,020,099 228,209,445 56.8 
10/10/2018 Control 4,397,809 135,648,525 30.8 
10/10/2018 Control 1,619,365 51,770,865 32.0 
10/10/2018 183 µg 4,122,368 262,234,095 63.6 
10/10/2018 183 µg 4,332,204 229,458,435 53.0 
10/10/2018 183 µg 4,465,682 256,434,885 57.4 
10/10/2018 183 µg 962,550 41,146,290 42.7 
10/10/2018 183 µg 4,276,994 184,493,265 43.1 
19/10/2018 183 µg 3,657,160 221,844,900 60.7 
19/10/2018 183 µg 3,897,451 304,626,825 78.2 
19/10/2018 183 µg 4,383,068 257,296,275 58.7 
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19/10/2018 Control 3,782,464 139,417,935 36.9 
19/10/2018 Control 4,105,156 202,080,360 49.2 
19/10/2018 Control 3,728,896 206,961,570 55.5 
19/10/2018 46 µg 4,137,498 233,067,960 56.3 
19/10/2018 46 µg 3,354,048 134,558,400 40.1 
19/10/2018 46 µg 3,051,308 202,563,840 66.4 
19/10/2018 183 µg 806,090 142,290,765 176.5 
19/10/2018 183 µg 3,612,450 425,048,535 117.7 
19/10/2018 183 µg 4,614,080 399,778,035 86.6 
19/10/2018 Control 4,107,235 154,017,195 37.5 
19/10/2018 Control 4,916,484 258,530,220 52.6 
19/10/2018 Control 4,826,125 216,654,885 44.9 
19/10/2018 46 µg 3,741,999 174,420,765 46.6 
19/10/2018 46 µg 4,000,874 334,227,735 83.5 
19/10/2018 46 µg 3,041,482 240,384,165 79.0 
19/10/2018 183 µg 2,774,652 289,204,935 104.2 
19/10/2018 183 µg 3,291,244 343,559,970 104.4 
19/10/2018 183 µg 3,228,384 389,319,210 120.6 
19/10/2018 Control 4,509,760 226,599,885 50.2 
19/10/2018 Control 3,911,691 214,071,480 54.7 
19/10/2018 Control 3,489,908 139,507,695 40.0 
19/10/2018 Control 3,385,591 156,437,400 46.2 
19/10/2018 Control 4,021,137 236,385,510 58.8 
19/10/2018 Control 4,692,477 222,925,080 47.5 
11/11/2018 46 µg 3,410,732 133,095,465 39.0 
11/11/2018 46 µg 2,218,341 186,084,720 83.9 
11/11/2018 46 µg 2,219,961 260,016,105 117.1 
11/11/2018 46 µg 2,639,329 74,746,620 28.3 





Table A4. Raw data for mean grey values of SKOV-3 implants stained for VEGF. 
Experiment 
Date 
Treatment Area (pixel2) Integrated 
density 
Mean grey value 
30/03/2015 0.3 µg 4,177,058 182,394,615 43.7 
30/03/2015 0.3 µg 5,507,884 404,078,100 73.4 
30/03/2015 0.3 µg 5,033,534 236,318,700 46.9 
10/10/2015 91 µg 4,244,898 262,618,890 61.9 
10/10/2015 91 µg 3,077,264 148,756,290 48.3 
10/10/2015 91 µg 2,114,245 100,818,585 47.7 
28/11/2015 91 µg 5,061,978 319,151,625 63.0 
28/11/2015 91 µg 6,031,788 304,257,840 50.4 
28/11/2015 0.3 µg 1,696,055 88,559,970 52.2 
28/11/2015 0.3 µg 3,367,713 255,945,795 76.0 
28/11/2015 0.3 µg 3,583,658 220,025,220 61.4 
28/11/2015 Control 5,185,974 669,061,860 129.0 
28/11/2015 Control 5,834,784 667,243,200 114.4 
28/11/2015 Control 5,708,428 632,859,255 110.9 
21/08/2017 183 µg 1,988,652 122,454,825 61.6 
21/08/2017 183 µg 3,772,664 244,964,985 64.9 
21/08/2017 183 µg 4,104,482 235,902,285 57.5 
21/08/2017 Control 2,838,632 111,020,880 39.1 
21/08/2017 Control 2,646,956 143,558,625 54.2 
21/08/2017 Control 4,010,331 172,798,455 43.1 
21/08/2017 183 µg 4,071,246 410,351,865 100.8 
21/08/2017 183 µg 3,484,444 366,846,570 105.3 
21/08/2017 183 µg 4,446,311 385,178,520 86.6 
21/08/2017 Control 5,933,854 352,193,505 59.4 
21/08/2017 Control 3,871,513 266,402,325 68.8 
21/08/2017 Control 5,859,881 385,318,770 65.8 
14/09/2017 0.3 µg 2,948,834 151,423,335 51.4 
14/09/2017 0.3 µg 2,087,200 165,978,225 79.5 
14/09/2017 0.3 µg 3,673,947 134,116,230 36.5 
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14/09/2017 Control 5,960,007 174,477,120 29.3 
14/09/2017 Control 3,306,601 135,795,150 41.1 
14/09/2017 Control 4,844,427 176,911,095 36.5 
07/02/2018 183 µg 4,453,929 168,146,745 37.8 
07/02/2018 183 µg 4,244,919 222,271,515 52.4 
07/02/2018 183 µg 4,555,311 162,143,535 35.6 
07/02/2018 Control 5,682,300 117,996,405 20.8 
07/02/2018 Control 5,128,871 242,277,030 47.2 
07/02/2018 Control 5,966,942 145,359,435 24.4 
01/09/2018 91 µg 3,196,808 247,994,385 77.6 
01/09/2018 91 µg 5,295,070 464,446,545 87.7 
01/09/2018 91 µg 5,371,628 411,864,525 76.7 
09/09/2018 91 µg 2,660,184 202,636,515 76.2 
09/09/2018 91 µg 2,786,221 217,353,075 78.0 
09/09/2018 91 µg 2,641,414 191,889,615 72.6 
09/09/2018 Control 4,162,536 323,192,100 77.6 
09/09/2018 Control 4,244,012 327,341,715 77.1 
09/09/2018 Control 4,645,258 366,221,310 78.8 
09/09/2018 91 µg 2,467,177 187,811,580 76.1 
09/09/2018 91 µg 2,766,797 372,889,050 134.8 
09/09/2018 91 µg 3,382,822 326,275,560 96.5 
09/09/2018 Control 4,654,492 343,789,215 73.9 
09/09/2018 Control 804,425 64,472,925 80.1 
09/09/2018 Control 3,374,568 240,793,440 71.4 
09/09/2018 91 µg 1,612,691 107,726,025 66.8 
09/09/2018 91 µg 1,898,188 144,812,460 76.3 





Table A5. Raw data for mean grey values of OVCAR-8 implants stained for Ki67. 
Experiment 
Date 
Treatment Area (pixel2) Integrated 
density 
Mean grey value 
01/11/2015 46 µg 433.1 687.0 1.6 
01/11/2015 46 µg 320.3 4,909.9 15.3 
01/11/2015 46 µg 442.0 332.7 0.8 
01/11/2015 Control 299.7 81.5 0.3 
01/11/2015 Control 587.7 151.8 0.3 
01/11/2015 Control 446.4 8,328.5 18.7 
11/11/2015 46 µg 308.5 50.2 0.2 
11/11/2015 46 µg 277.1 3,664.9 13.2 
11/11/2015 46 µg 285.0 7,912.2 27.8 
11/11/2015 46 µg 308.0 18,846.8 61.2 
11/11/2015 46 µg 384.4 9,045.4 23.5 
18/01/2016 0.3 µg 155.3 7,646.7 49.2 
18/01/2016 0.3 µg 159.6 6,851.7 42.9 
18/01/2016 0.3 µg 349.2 115.9 0.3 
18/01/2016 0.3 µg 293.5 3,183.6 10.8 
18/01/2016 0.3 µg 307.9 632.3 2.1 
18/01/2016 0.3 µg 284.2 30.6 0.1 
18/01/2016 0.3 µg 354.7 181.0 0.5 
18/01/2016 0.3 µg 273.4 6,005.3 22.0 
01/12/2017 Control 373.3 779.5 2.1 
01/12/2017 Control 448.4 210.0 0.5 
01/12/2017 Control 425.3 26,035.4 61.2 
10/10/2018 183 µg 260.3 313.3 1.2 
10/10/2018 183 µg 389.0 518.0 1.3 
10/10/2018 183 µg 459.6 159.1 0.3 
10/10/2018 Control 304.4 1,216.8 4.0 
10/10/2018 Control 381.0 25,757.3 67.6 
10/10/2018 Control 218.8 10,904.5 49.8 
10/10/2018 183 µg 227.5 1,041.7 4.6 
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10/10/2018 183 µg 427.2 11,219.5 26.3 
10/10/2018 183 µg 231.8 1,087.1 4.7 
10/10/2018 183 µg 457.4 18,904.2 41.3 
10/10/2018 183 µg 339.9 1,626.2 4.8 
19/10/2018 183 µg 152.0 3,523.2 23.2 
19/10/2018 183 µg 421.3 91.9 0.2 
19/10/2018 183 µg 385.8 16,357.4 42.4 
19/10/2018 Control 363.9 5,807.3 16.0 
19/10/2018 Control 351.1 15,945.1 45.4 
19/10/2018 Control 392.6 251.5 0.6 
19/10/2018 46 µg 316.6 20,987.8 66.3 
19/10/2018 46 µg 340.9 20,160.8 59.1 
19/10/2018 46 µg 401.1 8,654.4 21.6 
19/10/2018 183 µg 376.2 145.4 0.4 
19/10/2018 183 µg 269.6 13,052.6 48.4 
19/10/2018 183 µg 433.8 283.5 0.7 
19/10/2018 Control 288.4 4,681.9 16.2 
19/10/2018 Control 429.5 20,834.8 48.5 
19/10/2018 Control 391.6 1,416.5 3.6 
19/10/2018 46 µg 344.7 55.7 0.2 
19/10/2018 46 µg 432.4 15,360.3 35.5 
19/10/2018 46 µg 323.5 70.3 0.2 
19/10/2018 183 µg 225.3 21,487.0 95.4 
19/10/2018 183 µg 296.7 17,922.9 60.4 
19/10/2018 183 µg 336.6 164.9 0.5 
19/10/2018 Control 224.7 5,365.2 23.9 
19/10/2018 Control 384.8 25,135.2 65.3 
19/10/2018 Control 379.4 301.2 0.8 
19/10/2018 Control 326.2 12,192.7 37.4 
19/10/2018 Control 226.2 17,886.8 79.1 







Table A6. Raw data for mean grey values of SKOV-3 implants stained for Ki67. 
Experiment 
Date 
Treatment Area (pixel2) Integrated 
density 
Mean grey value 
30/03/2015 0.3 µg 234.7 154.2 0.7 
30/03/2015 0.3 µg 431.8 13,652.8 31.6 
30/03/2015 0.3 µg 610.3 16,300.3 26.7 
30/03/2015 0.3 µg 481.8 19,479.9 40.4 
30/03/2015 0.3 µg 599.9 57.6 0.1 
20/04/2015 Control 459.6 7,245.8 15.8 
20/04/2015 Control 566.9 8,851.2 15.6 
20/04/2015 Control 572.5 14,331.7 25.0 
10/10/2015 91 µg 353.8 6,080.3 17.2 
10/10/2015 91 µg 361.1 15.5 0.0 
28/11/2015 91 µg 112.1 7,278.8 64.9 
28/11/2015 91 µg 476.1 18,704.0 39.3 
28/11/2015 0.3 µg 153.4 0.9 0.0 
28/11/2015 0.3 µg 361.4 27,868.1 77.1 
28/11/2015 0.3 µg 328.9 3.8 0.0 
28/11/2015 Control 570.4 22,016.3 38.6 
28/11/2015 Control 629.9 45,514.5 72.3 
28/11/2015 Control 592.5 32,470.0 54.8 
21/08/2017 183 µg 458.7 13,279.8 28.9 
21/08/2017 183 µg 443.2 4,944.3 11.2 
21/08/2017 Control 506.1 26,532.4 52.4 
21/08/2017 Control 569.7 23,147.2 40.6 
21/08/2017 Control 353.3 85.6 0.2 
21/08/2017 183 µg 480.2 511.7 1.1 
21/08/2017 183 µg 269.5 2,889.6 10.7 
21/08/2017 183 µg 385.3 6,483.2 16.8 
14/09/2017 0.3 µg 182.3 15,717.9 86.2 
14/09/2017 0.3 µg 412.5 29,386.5 71.2 
14/09/2017 0.3 µg 422.1 1,298.5 3.1 
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14/09/2017 Control 265.6 17.4 0.1 
14/09/2017 Control 205.7 8,361.6 40.6 
14/09/2017 Control 595.0 14,480.0 24.3 
07/02/2018 183 µg 376.8 6,944.9 18.4 
07/02/2018 183 µg 567.5 31,972.6 56.3 
07/02/2018 Control 383.5 1,315.4 3.4 
07/02/2018 Control 546.9 12,535.4 22.9 
07/02/2018 Control 568.8 22,558.8 39.7 
01/09/2018 91 µg 332.6 6.4 0.0 
01/09/2018 91 µg 504.1 20,846.1 41.4 
01/09/2018 91 µg 455.8 14,760.5 32.4 
09/09/2018 91 µg 260.7 8,872.4 34.0 
09/09/2018 91 µg 292.0 9,432.7 32.3 
09/09/2018 91 µg 158.1 3,964.6 25.1 
09/09/2018 91 µg 152.5 5,429.7 35.6 
09/09/2018 91 µg 137.4 5,389.6 39.2 
09/09/2018 91 µg 537.0 555.5 1.0 
09/09/2018 Control 145.6 3,739.3 25.7 
09/09/2018 Control 334.8 822.2 2.5 
09/09/2018 Control 399.0 798.1 2.0 
09/09/2018 91 µg 159.5 4,029.6 25.3 
09/09/2018 91 µg 282.4 3,279.0 11.6 
09/09/2018 91 µg 267.2 1,717.4 6.4 
09/09/2018 Control 476.2 12,421.0 26.1 
09/09/2018 Control 426.6 17,122.9 40.1 









Treatment Area (pixel2) Integrated 
density 
Mean grey value 
01/11/2015 46 µg 4,973,759 62,629,020 12.6 
01/11/2015 46 µg 4,890,090 54,168,120 11.1 
01/12/2017 Control 2,502,931 42,191,025 16.9 
01/12/2017 Control 3,617,262 78,283,725 21.6 
01/12/2017 Control 3,617,154 35,548,785 9.8 
10/10/2018 Control 2,719,681 39,433,965 14.5 
10/10/2018 Control 2,905,619 21,645,675 7.4 
10/10/2018 Control 4,739,455 54,894,105 11.6 
18/01/2016 Control 1,824,068 27,208,500 14.9 
18/01/2016 Control 2,072,849 26,654,895 12.9 
19/10/2018 46 µg 2,710,430 17,521,815 6.5 
19/10/2018 46 µg 3,932,814 92,677,965 23.6 
19/10/2018 46 µg 4,134,591 115,344,150 27.9 
19/10/2018 46 µg 3,278,443 15,331,875 4.7 
19/10/2018 46 µg 4,716,035 50,129,940 10.6 
19/10/2018 46 µg 5,443,955 49,076,535 9.0 
19/10/2018 Control 3,152,760 22,940,055 7.3 
19/10/2018 Control 3,813,793 5,473,620 1.4 
19/10/2018 Control 3,937,129 32,128,910 8.2 
19/10/2018 Control 3,778,880 38,816,610 10.3 
19/10/2018 Control 2,819,814 32,712,930 11.6 
19/10/2018 Control 4,330,253 28,485,540 6.6 
19/10/2018 Control 2,587,889 23,386,305 9.0 
19/10/2018 Control 3,040,025 26,629,905 8.8 
19/10/2018 Control 4,581,971 28,944,030 6.3 
19/10/2018 Control 2,572,926 39,773,115 15.5 
19/10/2018 Control 3,253,738 52,673,055 16.2 
19/10/2018 Control 4,028,640 47,093,655 11.7 
115 
 
10/10/2018 183 µg 2,080,719 17,213,520 8.3 
10/10/2018 183 µg 3,386,860 30,359,280 9.0 
10/10/2018 183 µg 4,354,451 25,156,515 5.8 
10/10/2018 183 µg 1,225,342 13,134,540 10.7 
10/10/2018 183 µg 1,490,458 1,514,445 1.0 
10/10/2018 183 µg 2,887,418 6,421,155 2.2 
10/10/2018 183 µg 3,393,232 18,908,760 5.6 
10/10/2018 183 µg 3,522,119 32,645,100 9.3 
11/11/2018 46 µg 2,616,659 5,636,265 2.2 
11/11/2018 46 µg 3,538,631 58,129,290 16.4 
11/11/2018 46 µg 3,819,174 40,047,240 10.5 
11/11/2018 46 µg 3,361,691 42,955,770 12.8 
11/11/2018 46 µg 3,589,154 49,047,720 13.7 
19/10/2018 183 µg 2,143,295 3,102,840 1.4 
19/10/2018 183 µg 2,261,112 13,294,935 5.9 
19/10/2018 183 µg 3,964,831 40,260,930 10.2 
19/10/2018 183 µg 2,268,440 7,372,815 3.3 
19/10/2018 183 µg 3,372,332 4,670,580 1.4 









Treatment Area (pixel2) Integrated 
density 
Mean grey value 
10/10/2015 91 µg 4,452,434 37,260,345 8.4 
10/10/2015 91 µg 4,243,635 36,389,265 8.6 
28/11/2015 91 µg 5,452,711 109,505,415 20.1 
28/11/2015 91 µg 4,776,545 111,192,495 23.3 
28/11/2015 Control 2,766,174 61,931,595 22.4 
28/11/2015 Control 5,720,609 115,400,250 20.2 
28/11/2015 Control 5,491,457 113,631,825 20.7 
21/08/2017 Control 3,295,259 54,266,040 16.5 
21/08/2017 Control 3,190,435 20,667,750 6.5 
21/08/2017 Control 3,393,352 12,840,780 3.8 
21/08/2017 Control 5,620,718 59,736,045 10.6 
21/08/2017 Control 5,842,160 53,051,985 9.1 
21/08/2017 Control 5,382,241 11,022,885 2.0 
21/08/2017 183 µg 2,903,278 21,026,025 7.2 
21/08/2017 183 µg 3,519,325 13,022,340 3.7 
21/08/2017 183 µg 3,021,493 43,953,585 14.5 
21/08/2017 183 µg 3,625,888 13,653,210 3.8 
21/08/2017 183 µg 3,625,204 7,066,305 1.9 
21/08/2017 183 µg 4,131,436 23,760,900 5.8 
14/09/2017 Control 5,161,024 41,847,795 8.1 
14/09/2017 Control 4,017,193 41,613,450 10.4 
07/02/2018 183 µg 4,846,075 21,153,270 4.4 
07/02/2018 183 µg 4,681,315 28,728,045 6.1 
07/02/2018 183 µg 4,330,002 7,631,130 1.8 
07/02/2018 183 µg 2,644,180 35,137,725 13.3 
07/02/2018 183 µg 3,033,986 34,030,260 11.2 
07/02/2018 183 µg 3,344,333 30,453,885 9.1 
01/09/2018 91 µg 1,991,817 19,973,640 10.0 
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01/09/2018 91 µg 3,265,892 41,037,150 12.6 
01/09/2018 91 µg 4,984,383 65,767,305 13.2 
01/09/2018 Control 1,903,797 24,200,010 12.7 
01/09/2018 Control 1,848,003 3,231,360 1.7 
01/09/2018 Control 3,153,880 11,402,070 3.6 
01/09/2018 91 µg 3,581,692 39,219,765 11.0 
01/09/2018 91 µg 5,161,610 46,217,435 9.0 
09/09/2018 91 µg 2,255,002 51,257,040 22.7 
09/09/2018 91 µg 2,679,088 44,333,790 16.5 
 
 
